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Abstract 26 
Broad-spectrum β-lactamase genes (coding for extended-spectrum β-lactamases (ESBLs) and 27 
AmpC β-lactamases) have been frequently demonstrated in the microbiota of food-producing 28 
animals. This may pose a human health hazard since these genes may be present in zoonotic 29 
bacteria, which would cause a direct problem. They can also be present in commensals, which 30 
may act as a reservoir of resistance genes for pathogens causing disease both in humans and 31 
animals.  32 
Broad-spectrum β-lactamase genes are frequently located on mobile genetic elements, such as 33 
plasmids, transposons and integrons, which often also carry additional resistance genes. This 34 
could limit treatment options for infections caused by broad-spectrum β-lactam-resistant 35 
microorganisms. This review addresses the growing burden of broad-spectrum β-lactam 36 
resistance among Enterobacteriaceae isolated from food, companion and wild animals 37 
worldwide. To explore the human health hazard, the diversity of broad-spectrum β-lactamases 38 
among Enterobacteriaceae derived from animals is compared with respect to their presence in 39 
human bacteria. Furthermore, the possibilities of the exchange of genes encoding broad-40 
spectrum β-lactamases – including the exchange of the transposons and plasmids that serve as 41 
vehicles for these genes – between different ecosystems (human and animal) are discussed.  42 
43 
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Introduction 44 
Resistance to β-lactams in Enterobacteriaceae is mainly due to the production of β-45 
lactamases which may be encoded either chromosomally or on plasmids (Bradford, 2005). 46 
Resistance to extended-spectrum β-lactams has been associated with the production of broad-47 
spectrum β-lactamases such as extended-spectrum β-lactamases (ESBLs), AmpC β-48 
lactamases and metallo-β-lactamases (MBLs) (Batchelor et al., 2005a). ESBLs confer 49 
resistance to most β-lactam antibiotics, but are not active against cephamycins and 50 
carbapenems and are inactivated by β-lactamase inhibitors such as clavulanic acid. This is in 51 
contrast to AmpC β-lactamases, which are not inhibited by clavulanic acid and usually confer 52 
resistance to all β-lactams, with the exception of dipolar ionic methoxy-imino-cephalosporins, 53 
such as cefepime and the carbapenems (Bradford, 2005). MBLs can hydrolize all clinical β-54 
lactam substrates, with the exception of aztreonam.  55 
Broad-spectrum β-lactamase-producing Enterobacteriaceae have increasingly been detected 56 
in humans since the early 1990s and in animals since 2000 (Arlet et al., 2006; Bertrand et al., 57 
2006; Caratolli, 2008; Cloeckaert et al., 2007; Jacoby, 2009; Li et al., 2007; Paterson & 58 
Bonomo, 2005; Pitout & Laupland, 2008; Smet et al., 2008; Smet et al., 2009; Walsh, 2008). 59 
Resistance in bacteria of animals and its impact on human health have drawn much attention 60 
worldwide (Aarestrup, 2006; Phillips et al., 2004). The first pathway of resistance transfer is 61 
the direct transfer of a pathogen from animals to humans. This is the case for zoonotic agents 62 
such as Salmonella, where resistance against β-lactams, including extended-spectrum 63 
cephalosporins, has been demonstrated (Bertrand et al., 2006; Cloeckaert et al., 2007). 64 
Animals may also harbour resistance genes in their residing commensal flora. Commensal E. 65 
coli isolates have been implicated in the transmission of genetic resistance traits (Kruse & 66 
Sorum, 1994) because their resistance genes may jump from one bacterium to another, mainly 67 
by means of mobile genetic elements such as transposons and plasmids.  68 
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The present review analyses the growing burden of β-lactam resistance among 69 
Enterobacteriaceae of animals, focussing on the use of β-lactams in veterinary medicine and 70 
food-animal production, and on the β-lactamase genes and their ability to be transferred.  The 71 
diversity of broad-spectrum β-lactamases among Enterobacteriaceae from food-producing, 72 
companion and wild animals, as well as from humans, is compared and the possible 73 
movement across bacterial populations from different hosts is discussed.  74 
 75 
Use of β-lactam antimicrobials in veterinary medicine and food animal 76 
production   77 
One of the most important group of antimicrobial agents in veterinary medicine and food 78 
animal production are the β-lactams. These antimicrobial agents can be divided into different 79 
groups, three of which are used in veterinary medicine: the penicillins, the first- to fourth-80 
generation cephalosporins, and the β-lactamase inhibitors. An overview of the antimicrobial 81 
activity of the different β-lactam groups and their use in veterinary and human medicine is 82 
given in Table 1. The recommended use of β-lactams for the treatment of disease in swine, 83 
cattle, horses, poultry, cats and dogs is presented in Table 2. 84 
The different surveillance programs around the world have made it possible to obtain a good 85 
knowledge of β-lactam usage in food and non-food animals (Batchelor et al., 2005; 86 
Guardibassi et al., 2004; Hammerun & Heuer, 2009; Li et al., 2005; Lloyd, 2007; McEwan & 87 
Fedorka-Cray, 2006; Schwarz et al., 2001; Schwarz & Chaslus-Dancla, 2001; CIPARS, 2006; 88 
DANMAP, 2006; NARMS, 2004). By way of summary, ampicillin and amoxicillin are 89 
regarded as the drugs of choice in avian medicine in many continents. These drugs are used in 90 
most European countries, with the exception of Finland, Denmark and Sweden. In Spain, 91 
amoxicillin-clavulanic acid is also allowed for use (Schwarz & Chaslus-Dancla, 2001). Third-92 
generation cephalosporins are rarely used in poultry and only under very limited conditions 93 
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for treatment of valuable poultry stocks (Guardibassi et al., 2008). However, ceftiofur, 94 
licensed for veterinary use in the USA since 1988, has been given to one-day-old chickens to 95 
prevent early mortality in the USA (Batchelor et al., 2005). In Europe, cephalosporins are not 96 
allowed for use in poultry (Schwarz & Chaslus-Dancla, 2001; Smet et al., 2008), although 97 
extra-label use occurs.  98 
In cattle, pigs, horses, cats and dogs, aminopenicillins are often used. Third- and fourth-99 
generation cephalosporins have been approved as second choice treatment of different disease 100 
conditions such as metritis, foot rot and mastitis in cattle, respiratory disease in ruminants, 101 
horses and swine, and skin diseases in cats and dogs (Batchelor et al., 2005; Bradford et al., 102 
1999; Guardibassi et al., 2008; Mason & Kietzmann, 1999; Watson & Rosin, 2000).  103 
Besides their use in clinical therapy, β-lactams, especially penicillins, have been used as feed 104 
additives to improve growth. They were fazed out in Europe after the appearance of the 105 
“Swann Report” in 1975, in which concerns were raised that the use of antimicrobials for 106 
growth promotion could lead to increasing resistance in bacteria of human and animal origin 107 
(anonymous, 1968). However, in the USA penicillins are still used at subtherapeutic levels for 108 
growth promotion (Aarestrup, 2006).  109 
 110 
β-lactam resistance mechanisms 111 
All β-lactam agents have a four-membered β-lactam ring in their structure. A beta-lactam ring 112 
is a cyclic amide with a heteroatomic ring structure consisting of three carbon atoms and one 113 
nitrogen atom. These antimicrobial agents prevent the bacterial cell wall from forming by 114 
interfering with the final stage of peptidoglycan synthesis through acting on penicillin binding 115 
proteins (PBPS). The number of PBPS varies between bacterial species and these PBPS are 116 
found as both membrane-bound and cytoplasmatic proteins. The peptidoglycan layer 117 
maintains the cell shape and protects the bacterium against osmotic forces. In Gram-positive 118 
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bacteria, peptidoglycan forms a thick layer on the cytoplasmic membrane, whereas in Gram-119 
negative bacteria and mycobacteria, peptidoglycan is a thin layer sandwiched between the 120 
outer membrane and the cytoplasmic membrane (Giguère et al., 2006; Greenwood, 2000; 121 
Poole, 2004).  122 
Bacterial resistance to β-lactams can be due to at least three mechanisms. The first mechanism 123 
consists of mutations in genes encoding PBPS, the acquisition of alternative PPBS or the 124 
creation of mosaic PBPS. All these altered PBPS have a reduced affinity for β-lactams and as 125 
such can keep their function in maintaining the cell wall. The second mechanism consists of a 126 
change in the permeability of the cell wall. This may be due to alterations in the expression of 127 
porins or active efflux. The third mechanism, and by far the most common one, is the 128 
inactivation of the drug by β-lactamases (Batchelor et al., 2005; Poole, 2004; Massova & 129 
Mobashery; 1998; Shah et al., 2004). In this review the focus will be on the resistance 130 
mediated by β-lactamases, since this is the predominant mechanism of β-lactam resistance in 131 
Gram-negative bacteria, especially in Enterobacteriaceae. β-lactamases inactivate β-lactams 132 
by hydrolysing their four-membered β-lactam ring. They break a bond in the β-lactam ring to 133 
disable the molecule (Shah et al., 2004).  134 
 135 
β-lactamases: an overview 136 
Until now, more than 400 β-lactamases have been reported and new β-lactamases continue to 137 
emerge worldwide (Bradford, 2005; Gupta, 2007; Jacoby, 1991; Waalsh, 2008; Jacoby, 138 
2009). The main characteristics of the different families of β-lactamases, as presented in the 139 
brief overview below, are well documented on the following website: 140 
http://www.lahey.org/Studies/.  141 
 142 
 143 
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Extended-spectrum β-lactamases 144 
TEM-type β-lactamases 145 
More than 150 TEM-type β-lactamases have been found, and all of them are derivatives of 146 
TEM-1 or TEM-2 by point mutations. TEM-1 was first demonstrated in 1965 in an 147 
Escherichia coli isolate from a patient in Athens, Greece, named Temoneira (designation 148 
TEM) (Datta & Kontomichalou, 1965). In contrast to the majority of TEM β-lactamases, 149 
TEM-1, TEM-2 and TEM-13 are not ESBLs and are only able to hydrolyse penicillins. Some 150 
TEM derivatives have been found to have a reduced affinity for β-lactamase inhibitors and are 151 
called inhibitor resistant TEM (IRT). These enzymes have negligible activity against 152 
extended-spectrum cephalosporins and are not considered to be ESBLs (Chaibi et al., 1999). 153 
However, mutants of the TEM derivatives (called CMT-1, CMT-2, CMT-3 and CMT-4) have 154 
been identified that have the ability to hydrolyse both third-generation cephalosporins and β-155 
lactamase inhibitors (Fiett et al., 2000; Neuwirth et al., 2001).   156 
 157 
SHV-type β-lactamases 158 
Another family of β-lactamases are the SHV (sulfydryl variable) enzymes. The progenitor of 159 
the SHV enzymes, SHV-1, was first described in Klebsiella pneumoniae. SHV-1 confers 160 
resistance to broad-spectrum penicillins. In 1983, a Klebsiella ozaenae strain was isolated in 161 
Germany possessing a SHV-2 enzyme which efficiently hydrolyzed cefotaxime and, to a 162 
lesser extent, ceftazidime. To date, more than 50 SHV derivatives are known, all being 163 
derivatives of SHV-1 or SHV-2. Like the TEM-type enzymes, the majority of the SHV 164 
enzymes are ESBLs (Gupta, 2007; Paterson & Bonomo, 2005).  165 
 166 
 167 
 168 
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CTX-M-type β-lactamases 169 
A third family consists of the CTX-M enzymes, which are also ESBLs and were first isolated 170 
in Munich. The designation CTX-M reflects the hydrolytic activity of these β-lactamases 171 
against cefotaxime. It appears that the CTX-M-type β-lactamases are closely related to β-172 
lactamases of Kluyvera spp. CTX-M enzymes have 40% or less identity with TEM and SHV-173 
type ESBLs. So far, more than 70 CTX-M enzymes have been isolated. They are divided into 174 
5 clusters on the basis of the amino acid sequence: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-175 
9 and CTX-M-25 (Gupta, 2007; Paterson & Bonomo, 2005).  176 
 177 
OXA-type β-lactamases 178 
Most OXA-type β-lactamases, so named because of their oxacillin-hydrolizing capabilities, 179 
do not hydrolyse extended-spectrum cephalosporins and are not regarded as ESBLs. The 180 
exceptions to this rule are OXA-10 and OXA-13 to OXA-19 (Toleman et al., 2003). The 181 
evolution of ESBL OXA-type β-lactamases from parent enzymes with narrow spectra has 182 
many parallels with the evolution of TEM- and SHV-type ESBLs.  183 
 184 
Other examples of ESBLs 185 
PER (Pseudomonas extended-resistant), VEB (Vietnam extended-spectrum β-lactamase), 186 
BES (Brazil extended-spectrum), GES (Guiana extended-spectrum), TLA (named after 187 
Tlahuicas Indians), SFO (Serratia fonticola) and IBC (integron-borne cephalosporinase) are 188 
other examples of ESBLs that have been discovered (Gupta, 2007; Jacoby, 2006; Paterson & 189 
Bonomo, 2005). These enzymes are not so common among Enterobacteriaceae as the ESBLs 190 
described above. 191 
 192 
 193 
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AmpC β-lactamases 194 
Another large group of broad-spectrum β-lactamases are the AmpC enzymes, which are 195 
typically encoded on the chromosome of many Gram-negative bacteria, including 196 
Citrobacter, Serratia and Enterobacter species, where its expression is usually inducible 197 
(Jacoby, 2009). AmpC type β-lactamases may be carried on plasmids of bacterial species 198 
lacking the chromosomal ampC gene, such as Klebsiella spp. Plasmid-mediated AmpC 199 
enzymes have been found in E. coli, although this species can also increase production of its 200 
normally weakly expressed chromosomal AmpC enzyme by gene duplication or mutation in 201 
the ampC promoter or attenuator with consequent enhanced gene expression (Caroff et al., 202 
2000). Plasmid-mediated AmpC enzymes have been named – with inconsistency typical of β-203 
lactamase nomenclature – according to the resistance produced to cephamycins (CMY, 43 204 
varieties), cefoxitin (FOX, 7 varieties), moxalactam (MOX, 3 varieties) or latamoxef (LAT, 4 205 
varieties), according to the type of enzyme (ACC (Ambler class C), 4 varieties or ACT 206 
(AmpC type), 3 varieties), or according to the site of discovery, such as the Miriam Hospital 207 
in Providence (MIR-1) or the Dhahran Hospital in Saudi Arabia (DHA, 2 varieties). BIL-1 208 
was named after the patient (Bilal) who provided the original sample (Philippon et al., 2002). 209 
 210 
Metallo-β-lactamases 211 
The metallo-β-lactamases (MBL) are a molecularly diverse group of broad-spectrum β-212 
lactamases. They are widespread in Pseudomonas aeruginosa, Acinetobacter species (such as 213 
VIM (Verona integron-encoded metallo-β-lactamase) and OXA types) and have been more 214 
recently detected in Enterobacteriaceae (such as VIM, KPC (K. pneumoniae 215 
carbapenamases) and GES-types) (Jacoby, 2006; Walsh, 2008). So far, MBLs have not been 216 
detected in bacteria of animals, so this group of β-lactamases will not be reviewed further in 217 
this paper.   218 
 10 
Classification of broad-spectrum β-lactamases: a source of confusion 219 
Because of the diversity of the enzymatic characteristics of the β-lactamases, many attempts 220 
have been made to categorize these enzymes by using their biochemical attributes. Several 221 
different classification schemes for bacterial β-lactamases have been described. The two most 222 
often used of these systems will be discussed in this chapter. 223 
The first classification system, devised by Bush et al. (1995), is based on the activity of the ß-224 
lactamases against different ß-lactam antimicrobials (substrate specificity). It contains a wide 225 
variety of subgroups. Three major groups of enzymes can be defined: (1) cephalosporinases 226 
that are not greatly inhibited by clavulanic acid, (2) penicilinases, cephalosporinases and 227 
broad-spectrum β-lactamases that are inhibited by β-lactamase inhibitors, and (3) metallo-β-228 
lactamases (carbapenamases) that hydrolyze penicillins, cephalosporins and carbapenems 229 
with the exception of aztreonam (Bush et al., 1995).  230 
Recently, Giske et al. (2009) enlarged the ESBL definition with a view to achieving a balance 231 
between scientific and clinical needs. Several points of the Bush classification system were 232 
reconsidered, as described below.  233 
First, Bush et al. (1995) described ESBLs as enzymes that can be differentiated from their 234 
parental enzymes, which do not hydrolyse extended-spectrum β-lactams.  235 
Secondly, several β-lactamases (e.g. GES-5) that possess carbapenamase activity are still 236 
reported in the literature as ESBL.  237 
Third, the Bush classification system does not make a distinction between AmpC β-238 
lactamases of chromosomal origin and those of plasmid origin. However, plasmid-mediated 239 
AmpC enzymes have greater clinical importance from an infection control perspective than 240 
do their chromosomal counterparts (i.e. the added risk of transferable resistance genes).  241 
Finally, Bush et al. (1995) wrote that the classification scheme does not take into account the 242 
actual importance of phenotypic tests for β-lactamases.  243 
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So if scientific researchers adopt these points of the Bush classification system, there is little 244 
hope for the clinicians being properly informed about appropriate treatment. Thus, by 245 
broadening the ESBL definition, the communication with the clinicians and infection control 246 
practitioners will be largely enhanced (Giske et al., 2009).  247 
The second – and most widely used – classification scheme for β-lactamases is the Ambler 248 
system, which divides β-lactamases into four classes (A, B, C and D) on the basis of their 249 
amino acid sequences. At first, Ambler described two classes: class A β-lactamases (TEM, 250 
SHV and CTX-M enzymes), which have their active site at a serine residue, and class B 251 
enzymes (metallo-β-lactamases), which utilize a bivalent metal ion (zinc ion) to attack the β-252 
lactam ring (Ambler, 1980). Later on, when new insights were acquired, a novel class of 253 
serine β-lactamases, class C (AmpC β-lactamases), was defined. These showed little sequence 254 
similarity to the class A enzymes. And finally, another new class of serine β-lactamases, 255 
known as the OXA β-lactamases (class D), was identified (Ambler, 1980).  256 
A revision of the Ambler classification system by Hall & Barlow (2005) presupposed the 257 
existence of differences among the metallo-β-lactamases. They proposed to divide the class B 258 
enzymes into three subgroups: B1, B2 and B3. Members of subgroups B1 and B2 share many 259 
sequence similarities, but differ largely from the members of subgroup B3 (Hall & Barlow, 260 
2005).  261 
These different classification schemes have been and will continue to be updated according to 262 
the growing knowledge of the β-lactamases. It is better, however, not to abandon the existing 263 
classification systems, since they are widely used and well known, but rather to adapt them to 264 
the growing knowledge. 265 
 266 
 267 
 268 
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Mobility of broad-spectrum β-lactamase genes among Enterobacteriaceae 269 
β-lactamase (bla) genes encoding broad-spectrum β-lactamases have mainly been reported in 270 
Enterobacteriaceae and are associated with mobile genetic elements (MGEs), such as 271 
insertion sequences (ISs), integrons, transposons, plasmids and phage-related elements. It has 272 
to be noted that insertion sequences and transposons can hop from the chromosome to a 273 
plasmid or between plasmids or back to the chomosome within a bacterial cell, but require a 274 
conjugative element (plasmid or conjugative transposon) or phage to be mobilized between 275 
bacterial cells. The diversity of these genetic vehicles enhances the spread of broad-spectrum 276 
β-lactamases. What follows is an overview of these genetic elements.   277 
 278 
Mobile genetic elements described as carriers of ESBL genes 279 
MGEs for blaTEM genes 280 
All blaTEM genes are carried by three of the earliest described bacterial transposons, namely 281 
Tn1, Tn2 and Tn3. These transposons contain the transposase and resolvase genes, tnpA and 282 
tnpR, as well as a res resolution site. They are about 99% identical to each other, with most of 283 
the differences confined to a region close to the res site (Partidge & Hall, 2005). Most of the 284 
structures surrounding the blaTEM genes are Tn3-like transposons possessing 38 bp inverted 285 
repeats (IRs) (Heffron et al., 1979; Partidge & Hall, 2005). Table 3 shows a summary of all 286 
known blaTEM gene-transposon associations.  Some examples of blaTEM carrying transposons 287 
are given in Fig. 1A and 1B. 288 
 289 
MGEs for blaSHV genes  290 
Few studies have investigated the genetic support of blaSHV-like genes. These genes originate 291 
from the chromosome of Klebsiella pneumoniae and are spread together with other K. 292 
pneumoniae chromosomal DNA fragments from the chromosome to a plasmid within a 293 
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bacterial cell, following IS26-dependent mobilization (Fig. 1C). Their presence on a 294 
conjugative element makes them able to spread between Gram-negative bacteria (Carattoli et 295 
al., 2005; Chiaretto et al., 2008; Gangoué-Piéboji et al., 2005 ; Jouini et al., 2007 ; Miriagou 296 
et al., 2005; Poirel et al., 2008; Raskin et al., 2005; Riaño et al., 2006 ; Rodriguez-Baño et al., 297 
2008; Romero et al., 2005; Teshager et al., 2000; Tian et al., 2009; Yu et al., 2006). So far, 298 
the blaTEM and blaSHV genes have never been described in integron structures.  299 
 300 
MGEs for blaCTX-M genes  301 
Like the blaSHV genes, blaCTX-M genes are also mobilized from the chromosome of a naturally 302 
resistant bacterium. In this case, Kluyvera species are involved (Olson et al., 2005; Rodriguez 303 
et al., 2004). Several genetic elements such as the insertion sequences (IS) ISEcp1 and ISCR1 304 
and phage-related elements, which have been found to be involved in the mobility of blaCTX-M 305 
genes, are discussed below (Bae et al., 2007; Canton & Coque, 2006; Oliver et al., 2005; 306 
Poirel et al., 2008).  307 
ISEcp1-like elements belong to the IS1380 family of insertion sequences and have been 308 
identified in association with genes belonging to the blaCTX-M-1, blaCTX-M-2, blaCTX-M-25 and 309 
blaCTX-M-9 ESBL gene clusters (Bae et al., 2006a; Bae et al., 2006b; Eeckert et al., 2006; 310 
Fernandez et al., 2007; Liu et al., 2007; Navon-Venezia et al., 2008; Sheng et al., 2008). 311 
Extensive analysis has shown that ISEcp1 is responsible for the mobility of a transposition 312 
unit including itself and a blaCTX-M gene. This insertion sequence element is located upstream 313 
of a blaCTX-M gene. A schematic representation of this ISEcp1-like element in association with 314 
a blaCTX-M gene is given in Fig. 1D (Canton & Coque, 2006; Poirel et al., 2005a).  315 
Another, rather specific IS element found in association with blaCTX-M genes is the insertion 316 
sequence common region (ISCR1), formely known as orf513 (Partridge & Hall, 2003; Stokes 317 
et al., 1993). The function of this IS element remained unknown until comparative analysis 318 
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linked these so-called common region elements to a group of IS91-like insertion sequences 319 
(Toleman et al., 2006a). The IS91-like ISs are a family of unusual IS elements that differ 320 
from most other IS elements, both in structure and in mode of transposition. They can 321 
perform rolling-circle (RC) transposition, in which a single IS element can mobilize the 322 
sequences to which it is attached (del Pilar Garcillan-Barcia et al., 2001; Garcillan-Barcia et 323 
al., 2001; Tavakoli et al., 2000). It has been proposed that ISCR1 may mobilise the nearby 324 
sequence and a truncated 3’conserved sequence (CS) from one integron to the 3’CS of 325 
another integron through RC transposition, thus facilitating the formation of complex class 1 326 
integrons associated with ISCR1 (Toleman et al., 2006a; Toleman et al., 2006b), as shown in 327 
Fig. 1E (Bae et al., 2007; Canton & Coque, 2006; Garcia et al., 2005; Novais et al., 2006; 328 
Riaño et al., 2009).  329 
A third type of genetic elements associated with blaCTX-M genes are the phage-related 330 
elements (Fig. 1F) (Oliver et al., 2005). This highlights the fact that phages may serve as tools 331 
for natural genetic engineering processes that eventually lead to the evolution and spread of 332 
antimicrobial resistance (Muniesa et al., 2004; Oliver et al., 2005; Riaño et al., 2009).  333 
 334 
MGEs for other ESBL genes  335 
In contrast to the blaCTX-M genes, the blaVEB-1 gene was identified as a gene cassette in class 1 336 
integrons (Fig. 1G) (Girlich et al., 2001; Poirel et al., 1999; Poirel et al., 2005b). Moreover, 337 
the blaGES-1 gene was also found to be a gene cassette in a class 1 integron structure (Fig. 1H) 338 
(Poirel et al., 2000). Another study described the location of the blaGES-1 gene cassette on a 339 
class 3 integron (Fig. 1I) (Correia et al., 2003). These findings underlined the fact that 340 
integron-located ESBL genes are not only part of the Ambler class D (OXA-10) (Girlich et 341 
al., 2001) or class B (IMP-1, active on imipenem) (Miriagou et al., 2005), but may also be 342 
part of class A. This is of interest since most of the plasmid-mediated ESBL that are 343 
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spreading worldwide are of class A and their integron location may provide them additional 344 
potential for spreading. 345 
 346 
Mobile genetic elements described as carriers of ampC β-lactamase genes 347 
Many genetic elements have been found to be involved in the mobilization of ampC genes 348 
onto plasmids within a bacterium (D’Andrea et al., 2006; Jacoby & Tran, 1999; Queenan et 349 
al., 2001; Raskine et al., 2002; Winokur et al., 2001), the most important of which are 350 
discussed below.  351 
The insertion sequence ISEcp1 has been identified in association with many blaCMY genes, 352 
including the blaCMY-2 gene (Fig. 2A) (D’Andrea et al., 2006; Hopkins et al., 2006b; Hossain 353 
et al., 2004; Literacka et al., 2004; Nakano et al., 2007; Poirel et al., 1999; Poirel et al., 2000; 354 
Toleman et al., 2006b; Winokur et al., 2001; Wu et al., 1999) and the blaACC-1 and blaACC-4 355 
genes (Papagiannitsis et al., 2007; Partridge, 2007). ISEcp1 plays a dual role. It is not only 356 
responsible for the mobility of a transposition unit including itself and a resistance 357 
determinant, as was also described for blaCTX-M genes, but it can also supply an efficient 358 
promoter for the high level expression of neighbouring genes (Hossain et al., 2004) 359 
Other ampC genes, such as blaCMY-1, blaCMY-8, blaCMY-9, blaCMY-10, blaCMY-11, blaCMY-19 360 
blaMOX-1 and blaDHA-1, have been found downstream of an ISCR1 involved in gene 361 
mobilisation in complex class 1 integrons (Toleman et al., 2006b). This mobile genetic 362 
element has also been associated with blaCTX-M genes, as mentioned above. The schematic 363 
representation of blaDHA-1, blaCMY-10 and blaCMY-11 genes in association with ISCR1 in a 364 
complex class 1 integron is given in Fig. 2B.  365 
A Citrobacter freundii-derived sequence of 4,252 bp, which included a blaCMY-13 gene and 366 
was bound by two directly repeated IS26 elements, was found on an IncN plasmid from 367 
Escherichia coli (Fig. 2C), indicating that this gene may have spread, from the chromosome 368 
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to a plasmid within a bacterium, following IS26-dependent mobilization as was also described 369 
for blaSHV genes (Miriagou et al., 2004).  370 
 371 
Impact of mobile genetic elements as carriers of broad-spectrum β-lactamases on 372 
epidemiology and co-resistance selection   373 
Genes encoding broad-spectrum β-lactamases can be carried by a variety of MGEs such as 374 
insertion sequences, transposons and plasmids. These mobile genetic elements may have 375 
different potentials in the dissemination of resistances, such as ISEcp1, which seems to 376 
mobilise and transport genes onto plasmids quite easy and efficiently (Bae et al., 2006a; Bae 377 
et al., 2006b; Eeckert et al., 2006; Fernandez et al., 2007; Liu et al., 2007; Navon-Venezia et 378 
al., 2008; Sheng et al., 2008).  379 
The success of the spread of specific β-lactamases will thus be determined mainly by the 380 
MGEs in terms of the the selection and dispersion of these enzymes.  381 
The most striking examples of the impact of mobile genetic elements on the epidemiology 382 
and co-resistance selection are discussed below.  383 
 384 
MGE as a carrier for the blaTEM-52 gene 385 
The blaTEM-52 gene is located on a Tn3-like transposon that is found on a large stable 386 
conjugative IncI1 plasmid. This plasmid is found mainly in Enterobacteriaceae isolated from 387 
poultry and humans (Cloeckaert et al., 2007; Hasman et al., 2005; Smet et al., 2008; Smet et 388 
al., 2009). Surprisingly, until now, no other resistance genes have been associated with this 389 
plasmid. This is most probably due to its broad host spectrum and the possibility of its 390 
spreading internationally, though until now it has spread mainly in Europe (Weill et al., 2004; 391 
Cloeckaert et al., 2007; Hasman et al., 2005; Smet et al., 2008).  392 
 393 
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MGE as a carrier for the blaCTX-M-15 gene 394 
Another plasmid-mediated gene is blaCTX-M-15. This gene is associated with ISEcp1 and is 395 
mainly described in Enterobacteriaceae of human origin worldwide (Boyd et al., 2004; 396 
Hopkins et al., 2006c; Karisik et al., 2006; Lavollay et al., 2006; Nicolas-Chanoine et al., 397 
2008). This gene has been found on a multitude of plasmids of different sizes and with 398 
different incompatibility (Inc) groups, such as IncI1 and IncFII. The latter Inc group is 399 
frequently co-associated with replication genes originating from IncFIA or IncFIB (Hopkins 400 
et al., 2006c; Karisik et al., 2006). This indicates that the association with ISEcp1 is important 401 
in the spread of this gene among different plasmids. Besides the horizontal spread of a blaCTX-402 
M-15-carrying plasmid from one bacterium to another, the worldwide clonal spread of certain 403 
CTX-M-15-positive E. coli isolates has also been shown to be important in the dissemination 404 
of this resistance gene (Lavollay et al., 2006; Nicolas-Chanoine et al., 2008).  405 
 406 
 MGE as a carrier for the blaCTX-M-2 and blaCTX-M-9 genes 407 
Other blaCTX-M genes, such as the blaCTX-M-2 and blaCTX-M-9 genes, are located on plasmids, 408 
similarly to blaCTX-M-15, though they are associated with different Inc groups and are 409 
associated with ISCR1 as part of a complex class 1 integron, as already mentioned (Bae et al., 410 
2007; Canton & Coque, 2006; Garcia et al., 2005; Novais et al., 2006; Riaño et al., 2009). 411 
The blaCTX-M-2 and blaCTX-M-9 genes are mainly found on IncHI2 plasmids and may also be 412 
located on IncP, IncA/C or IncFI plasmids. The blaCTX-M-9 gene is also found on the 413 
chromosome (Fernandez et al., 2007; Hopkins et al., 2006c; Novais et al., 2006). These genes 414 
are found in Enterobacteriaceae from food-producing animals and humans. An important 415 
difference between blaCTX-M-9 and blaCTX-M-15 is the co-resistance caused by non-β-lactam 416 
resistance gene cassettes associated with these class 1 integrons. As such, these blaCTX-M-9 417 
genes may be easily selected by the use of other non-β-lactam antimicrobial agents 418 
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(Fernandez et al., 2007; Novais et al., 2006; Riaño et al., 2009; Sabaté et al., 2002). Similarly 419 
for blaCTX-M-2, however, a variety of non-β-lactam resistance gene cassettes have been found 420 
in these complex class 1 integrons, which makes them perfect discrimination tools (Arduino 421 
et al., 2002; Power et al., 2005; Valverde et al., 2006).  422 
 423 
MGE as a carrier for the blaCMY-2 gene  424 
The blaCMY-2 gene has been found to be located on an IncI1 or IncA/C plasmid (Hopkins et al., 425 
2006c). These plasmids seem to be very promiscuous, having been found all over the US, 426 
mainly associated with Salmonella (Winokur et al., 2000; Zhao et al., 2008). They are also 427 
emerging in other continents, though less in association with Salmonella (Briñas et al., 2005; 428 
Li et al., 2008; Pai et al., 2004; Su et al., 2005). This gene is like the blaCTX-M-15 gene 429 
associated with an ISEcp1-like element, which makes the spread of this bla gene between 430 
plasmids within a bacterium possible. Therfore, the dissemination of this gene could not be 431 
explained in terms of the clonal spread of CMY-2-producing bacteria, but rather in terms of 432 
different plasmids carrying a blaCMY-2 gene (Naseer et al., 2009; Winokur et al., 2001).  433 
 434 
Broad-spectrum β-lactamases among Enterobacteriaceae from animals 435 
Data on the presence of ESBL- and AmpC β-lactamase-producing Enterobacteriaceae 436 
isolated from healthy and sick animals are discussed in this section. Per group (food-437 
producing animals, companion animals and wild animals), ESBL-producing bacteria are 438 
handled first, followed by the AmpC β-lactamase-producing bacteria. 439 
 440 
 441 
 442 
 443 
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Food-producing animals 444 
Healthy animals 445 
Between 2002 and 2009, the number of publications reporting commensal broad-spectrum 446 
cephalosporin resistant Enterobacteriaceae isolated from food-producing animals has 447 
increased dramatically. A summary of the published data of ESBL- or AmpC β-lactamase-448 
producing bacteria isolated from food-producing animals is listed in Supplementary file 1.  449 
The diversity among the ESBL encoding genes in Enterobacteriaceae from food-producing 450 
animals is by far larger than what is seen for the AmpC encoding genes. So far, the presence 451 
of ESBLs among commensal Enterobacteriaceae has been found to range from 0.2 to 40.7% 452 
(Supplementary file 1). Some ESBLs seem to be confined to specific individual countries, 453 
such as TEM-106 in Belgium, CTX-M-8 and SHV-5 in Tunisia and several CTX-M enzymes 454 
in China (Duan et al., 2006; Jouini et al., 2007; Smet et al., 2008; Tian et al., 2009). Other 455 
ESBLs have been found to be more widely distributed. So far, TEM-52- and SHV-12-456 
producing Enterobacteriaceae, isolated especially from poultry, have only been described on 457 
the European continent (Supplementary file 1) (Briñas et al., 2003; Chiaretto et al., 2008; 458 
Cloeckaert et al., 2007; Costa et al., 2009; Hasman et al., 2005; Machado et al., 2008; Smet et 459 
al., 2008; Riaño et al., 2006). ESBLs such as CTX-M-1, CTX-M-2 and CTX-M-14 have been 460 
found in many European countries, being associated with E. coli mainly from poultry 461 
(Supplementary file 1) (Briñas et al., 2003; Costa et al., 2009; Girlich et al., 2007; Jouini et 462 
al., 2007; Kojima et al., 2005; Machado et al., 2008; Shiraki et al., 2004; Smet et al., 2008). 463 
The CTX-M-15 enzyme, the most widely diffused enzyme among human 464 
Enterobacteriaceae, was only recently detected among E. coli from poultry and pigs (Smet et 465 
al., 2008; Tian et al., 2009).   466 
The presence of AmpC β-lactamase mediated resistance in commensal Enterobacteriaceae 467 
ranged from 0.01 to 88.5% (Supplementary file 1). CMY-2 is the most common enzyme 468 
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identified among these isolates. On a dairy farm, the overwhelming presence of CMY-2-469 
producing E. coli (88.5% of the isolated strains) could be linked to the use of ceftiofur to treat 470 
respiratory infections in calves (Donaldson et al., 2006). There is a striking difference in the 471 
presence of CMY-2 between E. coli and Salmonella isolates from poultry, cattle and pigs in 472 
Japan and Canada (Supplementary file 1). This may indicate that there is somehow a different 473 
epidemiology of CMY-2-producing Enterobacteriaceae in those countries among different 474 
animal species.  475 
 476 
Sick animals  477 
To date, only a few studies have been published reporting ESBL or AmpC-producing 478 
Enterobacteriaceae isolated from sick pigs and cattle. The presence of ESBL- or AmpC-479 
producing bacteria among diseased poultry has so far not been described. An overview is 480 
given in the second part of Supplementary file 1.  481 
Data on the presence of ESBL-producing Enterobacteriaceae among diseased cattle and pigs 482 
have so far only been described in a Korean and a French report. TEM and SHV ESBLs have 483 
been described in Korea, whereas different members of the CTX-M family are predominantly 484 
present in France (Supplementary file 1) (Madec et al., 2008; Rayamajhi et al., 2008). 485 
AmpC enzymes have been detected among clinical bovine and porcine Enterobacteriaceae. 486 
The prevalence of these AmpC-producing animal pathogens varied from 0.3 to 77%. In most 487 
reports, CMY-2 enzymes and mutations in the promoter and attenuator regions of the 488 
chromosomal AmpC enzyme were found, but in one report DHA-1 enzymes were also found 489 
(Supplementary file 1).  490 
 491 
 492 
 493 
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Companion animals  494 
Healthy animals 495 
A few studies describing the presence (7 to 20%) of ESBL- or AmpC β-lactamase-producing 496 
E. coli isolated from the faecal microflora of healthy pets have been published 497 
(Supplementary file 2).  498 
ESBLs – predominantly CTX-M-1 – have not only found their way into commensal E. coli 499 
from dogs in Europe, but have also recently been found among commensal E. coli from cats 500 
and dogs in Latin America (Caratolli et al., 2005; Costa et al., 2004; Moreno et al., 2008).   501 
So far, CMY-2-producing E. coli have only been isolated from the faeces of healthy dogs in 502 
Italy (Carattoli et al., 2005).  503 
 504 
Sick animals 505 
Five recent prevalence studies are available on the presence of broad-spectrum β-lactamases 506 
in Enterobacteriaceae from sick companion animals with urinary tract infections. The 507 
presence of ESBL- or AmpC β-lactamase-producing E. coli from diseased dogs ranged from 508 
1.4% to 19.4% (Supplementary file 2). ESBLs of the CTX-M-1 cluster were the most 509 
predominant enzymes found. In four reports, CMY enzymes – mainly CMY-2 – were found, 510 
though CMY-7 enzymes were found in one study (Supplementary file 2). This is a situation 511 
similar to what is found in food-producing animals. However, the limited data available on 512 
broad-spectrum β-lactamases in pet animals is not sufficient to provide a good idea as to 513 
which broad-spectrum β-lactamases are spreading. Further epidemiological surveillance in pet 514 
animals should be performed to estimate the burden of this resistance.  515 
 516 
 517 
 518 
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Wild animals 519 
Healthy animals  520 
In Portugal, national surveillance in birds of prey and seagulls shows the emergence of broad-521 
spectrum β-lactamases among Enterobacteriaceae from wild animals (Costa et al., 2006; 522 
Poeta et al., 2008). To date, no AmpC β-lactamases have been identified. The occurrence of 523 
ESBLs was as high as 19% in E. coli isolates from faecal samples, mainly of birds of prey and 524 
seagulls, with a predominance of CTX-M-1, CTX-M-14 and TEM-52 enzymes 525 
(Supplementary file 3). A recent French study describes a 9.4% prevalence of commensal 526 
ESBL-producing E. coli from wild yellow-legged gulls. The most predominant ESBL was 527 
CTX-M-1 (Supplementary file 3). These enzymes were also found in the feacal flora of food-528 
producing animals and companion animals (Ho et al., 2008; Miro et al., 2005). The animals 529 
may have been contaminated by eating the leftovers from human food (Costa et al., 2006; 530 
Poeta et al., 2008). More studies should be performed in order to trace the origins of this 531 
contamination, including analysis of the prevalence of this type of resistance in different 532 
ecosystems.  533 
 534 
Broad-spectrum β-lactamases in animal-associated bacteria: significance 535 
for human health  536 
 537 
Presence of broad-spectrum β-lactamase-producing Enterobacteriaceae from humans 538 
In order to be able to compare differences and similarities between the situation in animal and 539 
human Enterobacteriaceae, the diversity of broad-spectrum β-lactamase-producing 540 
commensals and pathogens present in humans will first be discussed in this chapter. The 541 
ESBL-producing bacteria will first be discussed, followed by the AmpC β-lactamase-542 
producing bacteria. 543 
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Healthy humans 544 
Since 2000, the number of publications reporting the faecal carriage of broad-spectrum β-545 
lactamase-producing commensal Enterobacteriaceae from humans has been rising (Ho et al., 546 
2008; Kader et al., 2007; Kaneko et al., 2007; Leflon-Guibot et al., 2008; Miro et al., 2005; 547 
Moubareck et al., 2005; Pallechi et al., 2007; Pongpech et al., 2008; Rodriguez-Baño et al., 548 
2008; Valverde et al., 2004; Vinué et al., 2009). An overview of commensal broad-spectrum 549 
β-lactamase-producing bacteria, mainly E. coli, is given in Supplementary file 4. Most 550 
available publications describe the faecal carriage of ESBL-producing Enterobacteriaceae 551 
with a presence ranging from 0.6% as a lower limit in France (Leflon-Guibot et al., 2008) to 552 
the upper limit of 68% in Spain (Rodriguez-Baño et al., 2008) (Supplementary file 4). The 553 
most predominant family of ESBLs reported among commensal E. coli is the CTX-M family, 554 
with the CTX-M-9 cluster being the most common cluster worldwide (Supplementary file 4). 555 
This may indicate that commensal E. coli of humans may constitute a reservoir of blaCTX-M 556 
genes.  557 
So far, information about the presence of AmpC β-lactamase producing strains from faecal 558 
samples of healthy humans remains limited. In Japan, a prevalence of commensal CMY-2-559 
producing E. coli of 3.2% has been reported (Supplementary file 4). 560 
 561 
Sick humans 562 
Most studies dealing with the presence of broad-spectrum β-lactamases in bacteria from 563 
humans refer to pathogens. The occurrence of broad-spectrum β-lactamase-producing 564 
pathogens has already been extensively reviewed (Arlet et al., 2006; Jacoby, 20098; 565 
Livermore et al., 2007; Paterson et al., 2005; Pitout et al., 2005). Infections caused by 566 
Enterobacteriaceae complicate therapy and limit treatment options. Population studies of 567 
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human pathogens producing ESBLs or AmpC β-lactamases in hospitals and the community 568 
worldwide are summarized in Supplementary file 5.  569 
ESBL-producing human pathogens have been reported worldwide, with a presence of 0.3 to 570 
91% in Europe, 0.8 to 5.6% in North America and 12 to 31% in Africa and the Middle East. 571 
In the Asia and Pacific region, the presence of ESBL-producing pathogens ranges from 11.3-572 
38.6% (Supplementary file 5).  573 
ESBLs, such as TEM-52 and SHV-12, among human pathogens were first reported in Europe 574 
(Arlet et al., 1994; Arpin et al., 2003; Babini et al., 2000; De Gheldre et al., 2001; Knothe et 575 
al., 1983; Livermore et al., 2007; Politi et al., 2005; Saladin et al., 2002; Vahaboglu et al., 576 
2001; Weill et al., 2004). Later on, TEM-type ESBLs were described in the United States 577 
(Jacoby et al., 1988; Rice et al., 1996). Since then, CTX-M ESBLs have become dominant, 578 
with a much greater penetration into E. coli strains worldwide.  579 
There are considerable geographical differences in the occurrence of ESBLs, especially of the 580 
CTX-M enzymes. Many different CTX-M enzymes are widely distributed, mostly among E. 581 
coli, causing urinary tract infections (Brenwald et al., 2003; Doi et al., 2007; Livermore et al., 582 
2007; Paterson et al., 2005; Pitout et al., 2005). Some CTX-M enzymes seem to be dominant 583 
in specific European countries, such as CTX-M-14 and CTX-M-9 in Spain and Portugal 584 
(Garcia et al., 2005; Mendonça et al., 2007; Rodriguez-Baño et al., 2009; Romero et al., 585 
2005), CTX-M-1 and CTX-M-15 in Italy and France (Brigante et al., 2005; Carattoli et al., 586 
2008; Livermore et al., 2005) and CTX-M-15 in the United Kingdom (Livermore et al., 587 
2007). In the United States, the most common CTX-M-type ESBL is CTX-M-15, followed by 588 
CTX-M-16, CTX-M-8, and CTX-M-14 (Hanson et al., 2008; Lewis et al., 2007; Sjölund et 589 
al., 2008). Different CTX-M enzymes, with the predominance of CTX-M-15 and CTX-M-14, 590 
have also been reported among nosocomial and community acquired E. coli isolates causing 591 
urinary tract infections on the African and Asian continents (Bae et al., 2007; Cao et al., 592 
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2002; Chmelnitsky et al., 2005; Gangoué-Piéboji et al., 2005; Ho et al., 2005; Soge et al., 593 
2006; Song et al., 2009).  594 
AmpC β-lactamases have been found less frequently than ESBLs among Enterobacteriaceae. 595 
CMY-2 is the AmpC enzyme with the broadest geographic spread, being an important cause 596 
of β-lactam resistance in nontyphoid Salmonella strains in many countries. This type of 597 
resistance is increasing worldwide (Batchelor et al., 2005b; Dunne et al., 2000; Kruger et al., 598 
2004; Li et al., 2005; Su et al., 2005; Wichard et al., 2005; Winokur et al., 2000).   599 
The AmpC phenotype in E. coli is more often due to increased production of the 600 
chromosomal AmpC β-lactamase, as reported in a few prevalence studies (Bergström & 601 
Normark, 1979; da Silva Dias et al., 2008; Mammeri et al., 2008; Mulvey et al., 2005; Potz et 602 
al., 2006) (Table 8). However, CMY-producing E. coli strains, mainly CMY-2, have also 603 
been demonstrated (Supplementary file 5) (Adler et al., 2008; Gazouili et al., 1998; Hopkins 604 
et al., 2006a,b; Li et al., 2008; Moland et al., 2002; Mulvey et al., 2005; Pai et al., 2008; 605 
Pitout et al., 2007; Winokur et al., 2001).  606 
It seems that broad-spectrum β-lactamases have been evolving and spreading at a rapid rate 607 
among humans worldwide over the last 20 years.  608 
 609 
Differences and similarities between the situation in animal and human 610 
Enterobacteriaceae  611 
β-lactamases were first detected in the early 1980s in humans, and their presence and 612 
diversity have been increasing ever since. The first time cephalosporin resistance was noted in 613 
animals was in early 2000. Compared to what is known in humans, the knowledge of the 614 
epidemiology of broad-spectrum β-lactamase-producing bacteria in animals is rather limited. 615 
As the spread of these β-lactamases in animals only recently started to increase, it is possible 616 
that these genes may be of human origin (Hernadez et al., 2005). However, β-lactamases in 617 
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humans can also be of animal origin, as has been shown for the zoonotic Salmonella Infantis 618 
and Virchow isolates (Bertrand et al., 2006; Cloeckaert et al., 2007), in which cases the 619 
infecting cephalosporin resistant bacterium was directly derived from the animal. 620 
The diversity of broad-spectrum β-lactamases in human Enterobacteriaceae is much higher 621 
than the situation in animal bacteria (Fig. 3).  622 
In animals, there is a predominance of TEM-52, CTX-M-1, CTX-M-14 and CMY-2-623 
producing Enterobacteriaceae, with the predominance of CMY-2 in North-America, and of 624 
CTX-M-1, CTX-M-14 and TEM-52 enzymes in Europe (Allen & Poppe, 2002; Carattoli et 625 
al., 2005; Cloeckaert et al., 2007; Costa et al., 2004; Costa et al., 2006; Costa et al., 2009; 626 
Donaldson et al., 2006; Hasman et al., 2005; Machado et al., 2008; Smet et al., 2008; 627 
Winokur et al., 2000; Zhao et al., 2008).  628 
These enzymes, together with CTX-M-9 and CTX-M-15, are also predominantly present in 629 
human bacteria. Some enzymes in human bacteria are even limited to specific countries such 630 
as CTX-M-39 in Israël, CTX-M-13 in China, CTX-M-40 in Thailand, and TEM-63 and TEM-631 
131 in South Africa (Chmelnitsky et al., 2005; Ho et al., 2005; Kiratisin et al., 2008; Kruger 632 
et al., 2004). These enzymes have not been detected in animal Enterobacteriaceae. However, 633 
it must be said that the presence of these broad-spectrum β-lactamases in animal 634 
Enterobacteriaceae has not yet been investigated in these countries. 635 
The most prevalent enzymes in commensal and pathogenic E. coli from both humans and 636 
animals are CTX-M-9, SHV-12 and CTX-M-14 in Spain, CTX-M-14 and CTX-M-32 in 637 
Portugal, CTX-M-1 in France and Italy, CTX-M-2 in Japan and, finally, CMY-2 in Canada 638 
and the United States. This may indicate that there is somehow a similar epidemiology among 639 
animal and human bacteria. Comparison of the genetic relatedness of Enterobacteriaceae 640 
recovered from different countries and origins and harboring the same ESBL or AmpC 641 
enzyme may help to explain this hypothesis. 642 
 27 
 Impact on public health of animal-derived Enterobacteriaceae producing broad-643 
spectrum β-lactamases  644 
The presence of broad-spectrum β-lactamase-producing bacteria in animals is increasing, and 645 
it is not unrealistic to expect that this will have an impact on human health. Resistance may be 646 
transferred in two ways. Due to close contact or consumption of animal meat, a β-lactam 647 
resistant zoonotic strain, in most cases Salmonella spp., may be transferred directly from 648 
animal to human, thus possibly causing infection, as has been demonstrated in a number of 649 
reports (Bertrand et al., 2006; Cloeckaert et al., 2007; Espié et al., 2005; Fey et al., 2000; 650 
Riaño et al., 2009). As for direct transfer of resistance, the use of antimicrobial agents, 651 
selecting resistant bacteria may be the most important factor. However, the exact role of 652 
different antimicrobials in resistance development or dissemination remains unknown, though 653 
it could possibly be assessed by means of the pharmacokinetics and phamacodynamics of 654 
these antimicrobials. In vivo studies may also likely provide insights into the role of 655 
antimicrobial agents.  656 
Moreover, resistance may possibly be acquired indirectly, through the transfer of resistance 657 
genes from bacteria of animal origin to bacteria infecting humans. Studies pointing out the 658 
possibilities of indirect transfer of resistance genes remain limited.  659 
Cloeckaert et al., (2007) emphasised that TEM-52-producing Salmonella sp. are not only 660 
spreading between poultry and humans through direct transfer, but that the stable plasmid 661 
carrying this gene (Smet et al., 2009) may also be spreading between different Salmonella 662 
serotypes, thus indicating a possibility for indirect resistance transfer.  663 
Another example of indirect transfer of resistance is the dispersion of CMY-2-producing E. 664 
coli from cattle and pigs to humans, or vice versa, due to the association of this gene with 665 
ISEcp1 (Naseer et al., 2009; Hopkins et al., 2006; Winokur et al., 2001). Again, this 666 
highlights the importance of MGEs in the spread of resistance genes. 667 
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Therefore, both the selective effect of the antibiotics and the MGEs carrying these bla genes 668 
could be important factors in indirect resistance transfer. Little is known about the influence 669 
of these MGEs on the spread of the bla genes. This lack of knowledge could make it difficult 670 
to predict the possibilities of spread, thus underlining the need for further investigations.  671 
 672 
Concluding remarks 673 
The widespread use of extended-spectrum cephalosporins creates a reservoir of resistant 674 
bacteria and resistance genes that may add to the burden of β-lactam resistance in human 675 
medicine and shorten the time that these valuable antimicrobial compounds will be available 676 
for the effective treatment of infections. Moreover, multiresistance frequently associated with 677 
strains carrying ESBLs and AmpCs is worrisome since these strains can be selected by a 678 
manifold of different antimicrobial agents, which could dramatically reduce the treatment 679 
options.  680 
Resistance against β-lactams is increasingly being reported and is on the rise in 681 
Enterobacteriaceae from both humans and animals. This coincides with the increasing 682 
numbers of β-lactamase variants. It is also interesting to note that there is no specific β-683 
lactamase associated with animals since most enzymes are also predominantly present in 684 
bacteria found in humans. 685 
Some ESBLs and AmpC β-lactamases seem to be dedicated to a specific geographical region, 686 
while others are more widely spread. This appears to be without obvious reason. However, 687 
the wordwide detection of certain broad-spectrum β-lactamases does not seem to be linked to 688 
the expansion of bacterial clones, but rather to plasmid-mediated horizontal gene 689 
transmission. Epidemiological studies dealing with the dissemination of β-lactam resistance 690 
may help to explain these findings.  691 
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The understanding of why some MGEs seem to be very successful in spreading is of essential 692 
importance. Moreover, these MGEs frequently carry other resistance genes that are co-693 
transferred and cause co-resistance selection.  694 
The clinical and commercial pressure to use β-lactams, as well as the global mobility of 695 
humans, animals and food products guarantee that the spread of β-lactamase genes will 696 
continue. β-lactam antibiotics may enter the environment, such as water sources, having been 697 
excreted in the faeces and/or urine of treated animals. Water may therefore also be a potential 698 
source of selective pressure. 699 
More studies are needed to make a more accurate risk assessment concerning the spread of 700 
antimicrobial resistance, as well as on the mechanisms of linkage and transferability of β-701 
lactam resistance determinants in natural environments. Therefore, the evaluation of the 702 
possible impact of this resistance in animals for human health studies should not be limited to 703 
pathogenic bacteria, but must also include commensals, since they may be a major reservoir 704 
of resistance genes, as has already been shown to be the case in poultry (Smet et al., 2008).  705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 30 
References 716 
Aarestrup FM (2006) Antimicrobial resistance in bacteria of animal origin. ASM Press, 717 
 Washington, DC, USA.  718 
Adler H, Fenner L, Walter P, Hohler D, Schultheiss E, Oezcan S & Frei R (2008) Plasmid-719 
 mediated AmpC beta-lactamases in Enterobacteriaceae lacking inducible 720 
 chromosomal ampC genes: prevalence at a Swiss university hospital and occurrence of 721 
 the different molecular types in Switzerland. J Antimicrob Chemother 61: 457-458.  722 
Albertini MT, Benoit C, Berardi L, et al. (2002) Surveillance of methicillin-resistant 723 
 Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-724 
 spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre 725 
 incidence study. J Hosp Infect 52: 107-113. 726 
Allen KJ & Poppe C (2002) Occurrence and characterization of resistance to extended-727 
 spectrum cephalosporins mediated by beta-lactamase CMY-2 in Salmonella isolated 728 
 from food-producing animals in Canada. Can J Vet Res 66: 137-144. 729 
Ambler RP (1980) The structure of β-lactamases. Philos Trans R Soc Lond (Biol.) 289: 321-730 
331. 731 
Anonymous (1968) Joint Committee on the use of antibiotics in animal husbandry and 732 
veterinary medicine. Report. Her Majesty’s Stationery Ofice, London, United 733 
Kingdom. 734 
Arduino SM, Roy PH, Jacoby GA, Orman BE, Pineiro SA & Centron D (2002) blaCTX-M-2 is 735 
located in an unusual class 1 integron (In35) which includes Orf513. Antimicrob 736 
Agents Chemother 46: 2303-2306. 737 
Arlet G, Barrett TJ, Butaye P, Cloeckaert A, Mulvey MR & White DG (2006) Salmonella 738 
resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microb 739 
Infect 8: 1945-1954. 740 
 31 
Arlet G, Rouveau M, Casin I, Bouvet PJ, Lagrange PH, Philippon A (1994) Molecular 741 
epidemiology of Klebsiella pneumoniae strains that produce SHV-4 beta-lactamase 742 
and which were isolated in 14 French hospitals. J Clin Microbiol 32: 2553-2558.  743 
Arpin C, Dubois V, Coulange L, et al. (2003) Extended-spectrum β-lactamase-producing 744 
Enterobacteriaceae in community and private health care centers. Antimicrob Agents 745 
Chemother 47: 3506-3514. 746 
Babini GS & Livermore DM (2000) Antimicrobial resistance amongst Klebsiella spp. 747 
collected from intensive care units in Southern and Western Europe in 1997-1998. J 748 
Antimicrob Agents Chemother 45: 183-187.  749 
Bae IK, Lee YN, Lee WG, Lee SH & Jeong SH (2007) Novel complex class 1 integron 750 
bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene. 751 
Antimicrob Agents Chemother 51: 3017-3019. 752 
Bae IK, Lee BH, Hwang HY, Jeong SH, Hong SG, Chang CL, Kwak HS, Kim HJ & Youn H 753 
(2006a) A novel ceftazidime-hydrolising extended-spectrum β-lactamase, CTX-M-54, 754 
with a single amino acid substitution at position 167 in the omega loop. J Antimicrob 755 
Chemother 58: 315-319. 756 
Bae IK, Lee YN, Hwang HY, Jeong HS, Lee SJ, Kwak HS, Song W, Kim HJ & Youn H 757 
(2006b) Emergence of CTX-M-12 extended-spectrum β-lactamase-producing 758 
Escherichia coli in Korea. J Antimicrob Chemother 58: 1257-1259. 759 
Batchelor M, Threlfall EJ & Liebana E (2005a) Cephalosporin resistance among 760 
animal-associated Enterobacteria: a current perspective. Expert Rev Anti Infect Ther 3: 761 
403-417. 762 
Batchelor M, Hopkins KL, Threllfall EJ, Clifton-Hadley FA, Stallwood AD, Davies RH & 763 
 Liebana E (2005b) Characterization of AmpC-mediated resistance in clinical 764 
 32 
 Salmonella isolates recovered from humans during the period 1992 to 2003 in England 765 
 and Wales. J Clin Microb 43: 2261-2265. 766 
Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN & Sentry APAC Study Group (2002) 767 
 Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in 768 
 the Asia-Pacific region and South Africa: regional results from SENTRY 769 
 Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 42: 193-770 
 198.  771 
Bergström S & Normark S (1979) β-lactam resistance in clinical isolates of Escherichia coli 772 
 caused by elevated production of the ampC-mediated chromosomal β-lactamase. 773 
 Antimicrobial Agents Chemother 16: 427-433. 774 
Bertrand S, Weill FX, Cloeckaert A, et al. (2006) Clonal emergence of extended-spectrum 775 
 beta-lactamase (CTX-M-2)-producing Salmonella enterica serovar Virchow isolates 776 
 with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium 777 
 and France (2000 to 2003). J Clin Microb 44: 2897-2903.  778 
Bonnedahl J, Drobni M, Gauthier-Clerc M, Hernandez J, Granholm S, Kayser Y, Melhus A, 779 
 Kahlmeter G, Waldenström J, Johansson A & Olsen B (2009) Dissemination of 780 
 Escherichia coli with CTX-M type ESBL between humans and yellow-legged gulls in 781 
 the south of France. Plos one 4: e5958. 782 
Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, Bryce E, Gardam M, 783 
 Nordmann P, Mulvey MR & the Canadian Nosocomial Infection Surveillance 784 
 Srogram, Health Canada (2004). Complete nucleotide sequence of a 92-kilobase 785 
 plasmid harbouring the CTX-M-15 extended-spectrum beta-lactamase involved in an 786 
 outbreak in long term-care facilities in Toronto, Canada. Antimicrob Agents 787 
 Chemother 48: 3758-3764. 788 
 33 
Bradford PA (20015) β-lactamases in the 21st century: characterization, epidemiology and 789 
 detection of this important resistance threat. Clin Microbiol Rev 14: 933-951. 790 
Bradford PA, Petersen PJ, Fingerman IM & White DG (1999) Characterization of expanded-791 
 spectrum cephalosporin resistance in E. coli isolates associated with bovine calf 792 
 diarrhoeal disease. J Antimicrob Chemother 44: 607-610. 793 
Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA & Bush K (1994) Multiply resistant 794 
 Klebsiella pneumoniae strains from two Chicago hospitals: identification of the 795 
 extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in 796 
 a single isolate. Antimicrob Agents Chemother 38: 761-766. 797 
Brenwald  NP, Jevons G, Andrews JM, Xiong JH, Hawkey PM, Wise R (2003) An outbreak 798 
 of a CTX-M-type beta-lactamase-producing Klebsiella pneumoniae: the importance of 799 
 using cefpodoxime to detect extended-spectrum beta-lactamases. J Antimicrob 800 
 Chemother 51:195-196. 801 
Brigante G, Luzarro F, Perilli M, Lombardi G, Coli A, Rossolini GM, Amicosante G, Toniolo 802 
 A (2005) Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli 803 
 infecting hospital and community patients. Int J Antimicrob Agents 25: 157-162.  804 
Briñnas L, Lantero M, de Diego I, Alvarez M, Zarazaga M & Torres C (2005) Mechanisms of 805 
 resistance to extended-spectrum cepalosporins in Escherichia coli isolates recovered 806 
 in a Spanish hospital. J Antimicrob Chemother 56: 1107-1110. 807 
Briñas L, Moreno MA, Zarazaga M, Porrero C, Saénz Y, Garcia M, Dominguez L & Torres C 808 
 (2003) Detection of CMY-2, CTX-M-14, and SHV-12 β-lactamases in Escherichia 809 
 coli faecal-sample isolates from healthy chickens. Antimicrob Agents Chemother 47: 810 
 2056-2058. 811 
 34 
Bush K, Jacoby GA & Medeiros AA (1995) A functional classification scheme for β-812 
 lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 813 
 39: 1211-1233. 814 
Canton R & Coque TM (2006) The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9: 815 
 466-475. 816 
Cao V, Lambert T, Nhy DQ, Loan HK, Hoang NK, Arlet G & Courvalin P (2002) 817 
 Distribution of extended-spectrum β-lactamases in clinical isolates of 818 
 Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 46: 3739-3743. 819 
Carattolli A (2008) Animal reservoirs for extended-spectrum β-lactamase producers. Clin 820 
 Microbiol Infect 14: 117-123. 821 
Carattolli A, Lovari S, Franco A, Cordaro G, Matteo PD & Battisti A (2005) Extended-822 
 spectrum β-lactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, 823 
 from 2001 to 2003. Antimicrob Agents Chemother 49: 833-835. 824 
Carattoli A, García-Fernández A, Varesi P, Fortini D, Gerardi S, Penni A, Mancini C & 825 
 Giordano A (2008) Molecular epidemiology of Escherichia coli producing extended-826 
 spectrum beta-lactamases isolated in Rome, Italy. J Clin Microbiol 46: 103-108. 827 
Caroff N, Espaze E, Gautreau D, Richet H & Reynaud A (2000) Analysis of the effects of -42 828 
and -32 ampC promoter mutations in clinical isolates of Escherichia coli 829 
hyperproducing AmpC. J Antimicob Chemother 45: 783-788. 830 
Chaibi EB, Sirot D, Paul G & Labia R (1999) Inhibitor resistant TEM β-lactamases: 831 
 phenotypic genetic and biochemical characteristics. J Antimicrob Chemother 43: 447-832 
 458. 833 
Chiaretto G, Zavagnin P, Bettini F, Mancin M, Minorello C, Saccardin C & Ricci A (2008) 834 
 Extended-spectrum β-lactamase SHV-12-producing Salmonella from poultry. Vet 835 
 Microb 128: 406-413. 836 
 35 
Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ & Navon-Venezia S (2005) CTX-M-2 837 
 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in 838 
 multiple Escherichia coli clones isolates in Tel Aviv, Israel. Antimicrob Agents 839 
 Chemother 49: 4745-4750. 840 
Chouchani C, Ben-Achour N, M’Charek A & Belhadj O (2007) Cloning and sequencing the 841 
class A β-lactamase gene (blaTEM-15) located on a chromosomal Tn801 transposon. 842 
Diagn Microbiol Infect Dis 58: 459-463.  843 
CIPARS (2006) Canadian Integrated Program for Antimicrobial Resistance Surveillance 844 
 2004. Public Health Agency of Canada, Guelph, Ontario, Canada. 845 
Cloeckaert A, Praud K, Doublet B, Bertini A, Carattoli A, Butaye P, Imbrechts H, Bertrand S, 846 
 Collard JM, Arlet G & Weill FX (2007) Dissemination of an extended-spectrum-β-847 
 lactamase blaTEM-52 gene-carrying IncI1 plasmid in various Salmonella enterica 848 
 serovars isolated from poultry and humans in Belgium and France. Antimicrob Agents 849 
 Chemother 51: 1872-1875. 850 
Correia M, Boavida F, Grosso F, Salgado MJ, Lito LM, Melo Cristino J, Mendo S & Duarte 851 
 A (2003) Molecular characterization of a new class 3 integron in Klebsiella 852 
 pneumoniae. Antimicrob Agents Chemother 47: 2838-2843. 853 
Costa D, Poeta P, Brinas L, Saenz L, Rodrigues J & Torres C (2004) Detection of CTX-M-1 854 
 and TEM-52 β-lactamases in Escherichia coli strains from healthy pets in Portugal. J 855 
 Antimicrob Chemother 54: 960-961. 856 
Costa D, Poeta P, Saenz Y, Vinué L, Rojo-Bezares B, Jouini A, Zarazaga M, Rodrigues J & 857 
 Torres C (2006) Detection of Escherichia coli harbouring extended-spectrum β-858 
 lactamases of the CTX-M, TEM and SHV classes in faecal samples of wild animals in 859 
 Portugal. J Antimicrob Chemother 58: 1311-1312. 860 
 36 
Costa D, Vinué L, Poeta P, Coelho AC, Matos M, Saénz Y, Somalo S, Zarazaga M, 861 
 Rodrigues J & Torres C (2009) Prevalence of extended-spectrum beta-lactamase 862 
 producing Escherichia coli isolates in faecal samples of broilers. Vet Microb 863 
 doi:10.1016/j.vetmic.2009.03.029. 864 
D’Andrea MM, Nucleo E, Luzzaro F, Giani T, Migliavacca R, Vailati F, Kroumova V, 865 
 Pagani L & Rossolini GM (2006) CMY-16, a novel acquired AmpC-type β-lactamase 866 
 of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis 867 
 from northern Italy. Antimicrob Agents Chemother 50: 618-624. 868 
Da Silva Dias RC, Borges-Neto AA, D’Almeida Ferraiuoli GI, de-Oliveira MP, Riley LW & 869 
 Moreira BM (2008) Prevalence of AmpC and other β-lactamases in enterobacteria at a 870 
 large urban university hospital in Brazil. Diagn Microbiol Infect 60: 79-87.  871 
Datta N & Kontomichalou P (1965) Penicillinase synthesis controlled by infectious R factors 872 
 in Enterobacteriaceae. Nature 208: 239-241. 873 
De Gheldre Y, Struelens MJ, Glupczynski Y, De Mol P, Maes N, Nonhoff C, Chetoui H, Sion 874 
 C, Ronveaux O, Vaneechoutte M, Groupement pour le Dépistage, l’Etude et la 875 
 Prevention des Infections Hospitalières (GDEPIH-GOSPIZ) (2001) National 876 
 epidemiologic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 877 
 1998. J Clin Microbiol 39: 889-896. 878 
del Pilar Garcillan-Barcia M, Bernales I, Mendiola MV & de la Cruz F (2001) Single-879 
 stranded DNA intermediates in IS91 rolling-circle transposition. Mol Microbiol 39: 880 
 494-501. 881 
Doi Y, Adams J, O’Keefe A, Quereshi Z, Ewan L & Paterson DL (2007) Community 882 
 acquired extended-spectrum β-lactamase producers, United States. Emerg Infect Dis 7: 883 
 1121-1123.  884 
 37 
Donaldson SC, Straley BA, Hegde NV, Sawant AA, Debroy C & Jayarao BM (2006) 885 
 Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy 886 
 calves. Appl Environm Microbiol 72: 3940-3948. 887 
Duan RS, Sit TH, Wong SS, Wong RC, Chow KH, Mak GC, Yam WC, Ng LT, Yuen KY, 888 
 Ho PL (2006) Escherichia coli producing CTX-M beta-lactamases in food animals in 889 
 Hong Kong. Microb Drug Res 12: 145-148. 890 
Dubois V, Arpin C, Noury P, Quentin C (2002) Clinical strains of Pseudomonas aeroginosa 891 
 carrying a blaTEM-21 gene located on a chromosomal interrupted TnA type transposon. 892 
 Antimicrob Agents Chemother 46: 3624-3626. 893 
Dubois V, Arpin C, Noury P, Andre C, Coulange L & Quentin C (2005) Prolonged outbreak 894 
 of infection due to TEM-21-producing strains of Pseudomonas aeruginosa and 895 
 enterobacteria in a nursing home. J Clin Microbiol 43: 4129-4138. 896 
Dunne EF, Fey PD, Kludt P, et al. (2000) Emergence of domestically acquired ceftriaxone-897 
 resistant Salmonella infection associated with AmpC β-lactamase. JAMA 284: 3151-898 
 3156. 899 
Eeckert C, Gautier V & Arlet G (2006) DNA sequence analysis of the genetic environment of 900 
 various blaCTX-M genes. J Antimicrob Chemother 57: 14-23. 901 
Espié E, De Valk H, Vaillant V, Quelquejeu N, Le Querrec F & Weill FX (2005) An outbreak 902 
 of multidrug-resistant Salmonella enterica serovar Newport infections linked to the 903 
 consupmtion of imported horse meat in France. Epidemiol Infect 133: 373-376.   904 
Feria C, Ferreira E, Duarte Correia J, Gonçalvas J & Caniça M (2002) Patterns and 905 
 mechanisms of resistance to β-lactams and β-lactamase inhibitors in uropathogenic 906 
 Escherichia coli isolated from dogs in Portugal. J Antimicrob Chemother 49: 77-85. 907 
Fernandez AG, Cloeckaert A, Bertini A, Praud K, Doublet B, Weill FX & Carattoli A (2007) 908 
 Comparative analysis of IncHI2 plasmids carrying blaCTX-M-2 or blaCTX-M-9 from 909 
 38 
 Escherichia coli and Salmonella enterica strains isolated from poultry and humans. 910 
 Antimicrob Agents Chemother 51: 4177-4180. 911 
Fey PD, Safranex TJ, Rupp ME, Dunne EF, Ribot E, Iwen PC, Bradford PA, Angulo FJ & 912 
 Hinrichs S (2000) Cefrtiaxone-resistant Salmonella infection acquired by a child from 913 
 cattle. N Engl J Med 342: 1242-1249. 914 
Fiett J, Palucha A, Miaczynska B, Stankiewicz M, Przondo-Mordar-ska H, Hryniewics W & 915 
 Gniadkowski M (2000) A novel complex mutant beta-lactamase, TEM-68, identified 916 
 in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum beta-917 
 lactamase-producing klebsiellae. Antimicrob Agents Chemother 44: 1499-1505. 918 
Frye JG, Fedorka-Cray PJ, Jackson CR & Rose M (2008) Analysis of Salmonella enterica 919 
 with reduced susceptibility to the third-generation cephalosporin ceftriaxone isolates 920 
 from US cattle during 2000-2004. Microb Drug Res 4: 251-258. 921 
Gangoué-Piéboji J, Bedenic B, Koulla-Shiro S, Randegger C, Adiogo D, Ngassam P, Ndumbe 922 
 P & Hachler H (2005) Extended-spectrum β-lactamase-producing Enterobacteriacea 923 
 in Yaounde, Cameroon. J Clin Microb 43: 3273-3277. 924 
Garcia A, Navarro F, Miro E, Mirelis B, Campoy S & Coll P (2005) Characterization of the 925 
 highly variable region surrounding the blaCTX-M-9 gene in non-related Escherichia 926 
 coli from Barcelona. J Antimicrob Chemother 56: 819-826. 927 
Gazouli M, Tzouvelekis LS, Vatopoulos AC & Tzelepi E (1998) Transferable class C β-928 
 lactamases in Escherichia coli strains isolated in Greek hospitals and characterization 929 
 of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii 930 
 AmpC β-lactamase. J Antimicrob Chemother 42: 419-425. 931 
Giguère S, Prescott JF, Baggot JP, Walker RD & Dowling PM (2006) Antimicrobial therapy 932 
 in veterinary medicine. Blackwell Publishing, Oxford, UK. 933 
 39 
Giles WP, Benson AK, Olsen ME, Hutkins RW, Whichard JM, Winokur PL & Fey PD 934 
 (2004) DNA sequence analysis of regions surrounding blaCMY-2 from multiple 935 
 Salmonella plasmid backbones. Antimicrob Agents Chemother 48: 2845-2852.  936 
Girlich D, Poirel L, Carattoli A, Kempf I, Lartigue M-F, Bertini A & Normann P (2007) 937 
 Extended-spectrum β-lactamase CTX-M-1 in Escherichia coli isolates from healthy 938 
 poultry in France. Appl Environ Microb 73: 4681-4685. 939 
Girlich D, Poirel L, Leelaporn A, Karim A, Tribuddharat C, Fennewald M, Nordmann P 940 
 (2001) Molecular epidemiology of the integron-located VEB-1 extended-spectrum 941 
 beta-lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand. J Clin 942 
 Microb 39: 175-182. 943 
Giske CG, Sundsfjord AS, Kahlmeter G, Woodford N, Nordmann P, Paterson DL, Canton R, 944 
 Walsh TR (2009) Redefining extended-spectrum β-lactamases: balancing science and 945 
 clinical need – authors’ response. J Antimicrob Chemother Doi:10.1093/jac/dkp143.  946 
Greenwood D (2000) Antimicrobial Chemotherapy. Oxford University Press, New York, 947 
 USA.  948 
Guardabassi L, Jensen LB & Kruse H (2008) Antimicrobial Use in Animals. Blackwell 949 
 Publishing, Oxford, UK. 950 
Gupta V (2007) An update on newer β-lactamases. Indian J Med Res 126: 417-427. 951 
Gupta A, Fontana J, Crowe C, Bolstorff B, Stout A, Van Duyne S, Hoekstra MP, Whichard 952 
 JM, Barrett TJ & Angulo FJ (2003) Emergence of multidrug-resistant Salmonella 953 
 enterica serotype Newport Infections resistant to expanded-spectrum cephalosporins 954 
 in the United States. J Clin Infect 188: 1707-1716. 955 
Hall BG & Barlow M (2005) Revised Ambler classification of β-lactamases. J Antimicrob 956 
 Chemother 55: 1050-1051. 957 
 40 
Hammerum AM & Heuer OE (2009) Human health hazards from antimicrobial-resistant 958 
 Escherichia coli of animal origin. Clin Infect Dis 48: 916-921. 959 
Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ & Cavalieri SJ (2008) Surveillance 960 
 of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and 961 
 OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia 962 
 coli in a U.S. community. Antimicrob Agents Chemother 52: 3814-3816. 963 
Hasman H, Mevius D, Veldman K, Olesen I & Aarestrup FM (2005) β-lactamases amoung 964 
 extended-spectrum β-lactamase (ESBL)-resistant Salmonella from poultry, poultry 965 
 products and human patients in the Netherlands. J Antimicrob Chemother 56: 115-121. 966 
Heffron F, McCarthy BJ, Ohtsubo E (1979) DNA sequence analysis of the transposon Tn3: 967 
 three genes and three sites involved in transposition of Tn3. Cell 18: 1153-1163.  968 
Hernadez JR, Martinez-Martinez L, Canton R, Coque TM, Pascual A & Spanish Group for 969 
 Nosocomial Infections (GEIH) (2005) Nationwide study of Escherichia coli and 970 
 Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. 971 
 Antimicrob Agents Chemother 49: 2122-2125. 972 
Ho PL, Wong RCW, Chow KH, Yip K, Wong SSY & Que TL (2008) CTX-M type beta-973 
 lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non-974 
 hospitalised children and adults. J Microbiol Immunol Infect 41: 428-432. 975 
Ho PL, Ho AYM, Chow KH, Wong RCW, Duan RS, Ho WL, Mak GC, Tsang KW, Yam 976 
 WC & Yuen KY (2005) Occurrence and molecular analysis of extended-spectrum β-977 
 lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002. J Antimicrob 978 
 Chemother 55: 840-845. 979 
Hopkins KL, Batchelor MJ, Liebana E, Deheer-Graham AP, Threlfall EJ (2006a) 980 
 Characterisation of CTX-M and AmpC genes in human isolates of Escherichia coli 981 
 41 
 identified between 1995 and 2003 in England and Wales. Int J Antimicrob Chemother 982 
 28: 180-192.  983 
Hopkins KL, Deheer-Graham A, Karisik E, Batchelor MJ, Liebana E & Threlfall EJ (2006b) 984 
 New plasmid-mediated AmpC β-lactamase (CMY-21) in Escherichia coli isolates in 985 
 the UK. Int J Antimicrob Agents 28: 80-82. 986 
Hopkins KL, Liebana E, Villa L, Batchelor M, Threllfall EJ & Carattoli A (2006c) Replicon 987 
 typing of plasmids carrying CTX-M or CMY β-lactamases circulating among 988 
 Salmonella and Escherichia coli isolates. Antimicrob Agents Chemother 50: 3203-989 
 3206. 990 
Hornish RE & Kotarski SF (2002) Cephalosporins in veterinary medicine –ceftiofur use in 991 
 food animals. Curr Top Med Chem 2: 717-731.  992 
Hossain A, Reisbig MD & Hanson ND (2004) Plasmid-encoded functions compensate for the 993 
 biological cost of AmpC overexpression in a clinical isolate of Salmonella 994 
 typhimurium. J Antimicrob Chemother 53: 964-970. 995 
Jacoby GA (2006) β-lactamases nomenclatuur. Antimicrob Agents Chemother 50: 1123- 1129. 996 
Jacoby GA (2009) AmpC β-lactamases. Clin Microb Rev 22: 161-182. 997 
Jacoby GA & Medeiros AA (1991) More extended-spectrum β-lactamases. Antimicrob 998 
 Agents Chemother 35: 1697-1704. 999 
Jacoby GA & Tran J (1999) Sequence of the MIR-1 β-lactamase gene. Antimicrob Agents 1000 
 Chemother 43: 1759-1760. 1001 
Jacoby GA, Medeiros AA, O’Brien TF, Pinto ME & Jiang H (1988) Broad-spectrum, 1002 
 transmissible beta-lactamases. N Engl J Med 319: 723-724. 1003 
Jouini A, Vinué L, Slama KB, Saénz Y, Klibi N, Hammami S, Boudabous A & Torres C 1004 
 (2007) Characterization of CTX-M and SHV extended-spectrum β-lactamases and 1005 
 42 
 associated resistance genes in Escherichia coli strains of food samples in Tunesia. J 1006 
 Antimicrob Chemother 60: 1137-1141. 1007 
Kader AA, Kumar A & Kamath KA (2007) Fecal carriage of Extended-spectrum β-1008 
 lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and 1009 
 asymptomatic healthy individuals. Infect Control Hosp Epidemiol 28: 1114-1116.  1010 
Kaneko K, Sato Y, Tokunaga SK, Tamaki SK, Okamoto R & Matsuhisa I (2005) AmpC β-1011 
 lactamase-mediated cefpodoxime-resistant Escherichia coli isolated from from faecal 1012 
 samples of healthy volunteers. J Antimicrob Chemother 52: 369-371. 1013 
Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM & Woodford N (2006) 1014 
 Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from 1015 
 Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 58: 665-668. 1016 
Kiratisin P, Apisarnthanarak A, Laesripa C & Saifon P (2008) Molecular characterization and 1017 
 epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and 1018 
 Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, 1019 
 where the CTX-M family is endemic. Antimicrob Agents Chemother 52: 2818-2824. 1020 
Knothe H, Shah P, Kremery V, Antal M & Mitsuhashi (1983) Transferable resistance to 1021 
 cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella 1022 
 pneumoniae and Serratia marcescens. Infection 11: 315-317.  1023 
Kojima A, Ishii Y, Ishihara K, Esaki H, Asai T, Oda C, Tamura Y, Takahashi T & 1024 
 Yamaguchio K (2005) Extended-spectrum-β-lactamase-producing Escherichia coli 1025 
 strains isolated from farm animals from 1999 to 2002: report from the Japanese 1026 
 veterinary antimicrobial resistance monitoring program. Antimicrob Agents 1027 
 Chemother 49: 3533-3537. 1028 
Kozak GK, Boerlin P, Janecko N, Reid-Smith RJ & Jardine C (2009) Antimicrobial resistance 1029 
 in Escherichia coli isolates from swine and wild small mammals in the proximity of 1030 
 43 
 swine farms and in natural environments in Ontario, Canada. Appl Environ Microb 75: 1031 
 559-566. 1032 
Kruger T, Szabo D, Keddy KH, Deeley K, Marsh JW, Hujer AM, Bonomo RA & Paterson 1033 
 DL (2004) Infections with nontyphoidal Salmonella species producing TEM-63 or a 1034 
 novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother 48: 1035 
 4263-4270.  1036 
Kruse H & Sorum H (1994) Transfer of multiple drug resistance plasmids between bacteria of 1037 
 diverse origins in natural microenvironments. Appl Environ Microbiol 60: 4015-4021. 1038 
Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Redjeb SB, Bercion R, Gautier 1039 
 V & Arlet G (2006) Clonal dissemination of a CTX-M-15 β-lactamase-producing 1040 
 Escherichia coli strain in the Paris area, Tunis and Bangui. Antimicrob Agents 1041 
 Chemother 50: 2433-2438. 1042 
Lee JH, Jung HI, Jung JH, Park SP, Ahn JB, Jeong SH, Jeong BC, Lee, JH & Lee SH (2004) 1043 
 Dissemination of transferable AmpC-type β-lactamase (CMY-10) in a Korean 1044 
 hospital. Microb Drug Res 10: 224-230.  1045 
Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L & Nicolas-Chanoine MH (2008) 1046 
 Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, 1047 
 among faecal Escherichia coli isolates from healthy subjects living in the area of Paris, 1048 
 France. J Clin Microbiol 46: 3900-3905. 1049 
Lewis JS, Herrera M, Wickes B, Patterson JE & Jorgensen JH (2007) First report of the 1050 
 emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the 1051 
 predominant ESBL isolated in a U.S. health care system. Antimicrob Agenets 1052 
 Chemother 51: 4015-4021. 1053 
Li XZ, Mehrotra M, Ghimire S & Adewoye L (2007) β-lactam resistance and β-lactamases in 1054 
 bacteria of animal origin. Vet Microbiol 121: 197-214. 1055 
 44 
Li Y, Li Q, Du Y, Jiang X, Tang J, Wang, Li G & Jiang Y (2008) Prevalence of plasmid-1056 
 mediated AmpC β-lactamases in a Chinese university hospital from 2003-2005: first 1057 
 report of CMY-2-type AmpC β-lactamase resistance in China. J Clin Microb 46: 1058 
 1317-1321. 1059 
Li WC, Huang FY, Liu CP, Weng LC, Wang NY, Chiu NC & Chiang CS (2005) Ceftriaxone 1060 
 resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan 1061 
 attributable to production of CTX-M-14 and CMY-2 β-lactamases. J Clin Microbiol 1062 
 43: 3237-3243.  1063 
Liebana E, Batchelor M, Hopkins KL, Clifton-Hadley FA, Taele CJ, Foster A, Barker L, 1064 
 Threlfall EJ & Davies RH (2006) Longitudinal farm study of extended-spectrum β-1065 
 lactamase-mediated resistance. J Clin Microb 44: 1630-1634. 1066 
Liebana E, Gibbs M, Clouting C, Barker L, Clifton-Hadley FA, Pleydell E, Abdalhamid B, 1067 
 Hanson ND, Martin L, Poppe C & Davies RH (2004) Characterization of β-1068 
 lactamases responsible for resistance to extended-spectrum cephalosporins in 1069 
 Escherichia coli and Salmonella enterica strains from food-producing animals in 1070 
 the United Kingdom. Microb Drug Res 10: 1-9.  1071 
Literacka E, Empel J, Baraniak A, Sadowy E, Hryniewicz W & Gniadkowski M (2004) Four 1072 
 variants of the Citrobacter freundii AmpC-type cephalosporinases, including novel 1073 
 enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. 1074 
 Antimicrob Agents Chemother 48: 4136-4143.  1075 
Liu SY, Su LH, Yeh YL, Chu C, Lai JC & Chiu CH (2007) Characterization of plasmids 1076 
 encoding CTX-M-3 extended-spectrum β-lactamase from Enterobacteriaceae isolated 1077 
 at a university hospital in Taiwan. Int J Antimicrob Chemother 29: 440-445. 1078 
Livermore DM & Hawkey PM (2005) CTX-M: changing the face of ESBLs in the UK. J 1079 
 Antimicrob Chemother 56: 451-454. 1080 
 45 
Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, 1081 
 Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L & Woodford N (2007) CTX- 1082 
 M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59: 165-174. 1083 
Lloyd DH (2007) Reservoirs of antimicrobial resistance in pet animals. Clin Infect Dis 45: 1084 
 S148-S152. 1085 
Mabilat C, Lourencao-Vital J, Goussard S & Courvalin P (1992) A new example of a physical 1086 
 linkage between Tn1 and Tn21: the antibiotic multiple-resistance region of 1087 
 plasmid pCFF04 encoding extended-spectrum β-lactamase TEM-3. Mol Gen Genet 1088 
 235: 113-121.  1089 
Machado E, Coque TM, Canton R, Sousa JC & Peixe L (2008) Antibiotic resistance integrons 1090 
 and extended-spectrum β-lactamases among Enterobacteriaceae isolates recovered 1091 
 from chickens and swine in Portugal. J Antimicrob Chemother 62: 296-302. 1092 
Madec JY, Lazizzera C, Châtre P, Meunier D, Martin S, Lepage G, Ménard MF, Lebreton P, 1093 
 Ramboud T (2008) Prevalence of fecal carriage of acquired-expanded-spectrum 1094 
 cephalosporin resistance in Enterobacteriaceae strains from cattle in France. J Clin 1095 
 Microb 46: 1566-1567.  1096 
Mammeri H, Eb F, Berkani A & Nordmann P (2008) Molecular characterization of AmpC-1097 
 producing Escherichia coli clinical isolates recovered in a French hospital. J 1098 
 Antimicrob Chemother 61: 498-503. 1099 
Massova I & Mobashery S (1998) Kinship and diversification of bacterial penicillin-binding 1100 
 proteins and β-lactamases. Antimicrob Agents Chemother 42: 1-17. 1101 
Mason IS & Kietzmann M (1999) Cephalosporins-pharmacological basis of clinical use in 1102 
 veterinary dermatology. Vet. Dermatol. 10: 187-192.  1103 
McEwan SA & Fedorka-Cray PJ (2006), (eds.). Animal antimicrobial use data collection in 1104 
 the United States: methodological options. Clin Infect Dis 73 (2-3): 105-228. 1105 
 46 
Mendonça N, Leitao J, Manageiro V, Ferreira E, of the Antimicrobial Resistance Surveillance 1106 
 Program in Portugal & Caniça M (2007) Spread of Extended-spectrum β-lactamase 1107 
 CTX-M-producing Escherichia coli clinical isolates in community and nosocomial 1108 
 environments in Portugal. Antimicrob Agents Chemother 51: 1946-1955.  1109 
Miriagou V, Carattoli A, Tzelepi E, Villa L & Tzouvelekis LS (2005) IS26-associated In4-1110 
 type integrons forming multiresistance loci in enterobacterial plasmids. Antimicrob 1111 
 Agents Chemother 49: 3541-3543. 1112 
Miriagou V, Tzouvelekis LS, Villa L, Lebessi E, Vatopoulos AC, Caratolli A & Tzelepi E 1113 
 (2004) CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli 1114 
 plasmid. Antimicrob Agents Chemother 48: 3172-3174. 1115 
Miro E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, Gomez L & Coll P (2005) 1116 
 Surveillance of extended-spectrum β-lactamases from clinical samples and faecal 1117 
 carriers in Barcelona, Spain. J Antimicrob Chemother 56: 1152-1155.  1118 
Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS (2002) Occurrence 1119 
 of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. 1120 
 Antimicrob Agents Chemother 46: 3837-3842. 1121 
Moubareck C, Daoud Z, Hakimé NI, Hamzé M, Mangeney N, Matta H, Mokhbat JE, Rohban 1122 
 R, Sarkis DK, Doucet-Populaire F (2005) Countrywide spread of community- and 1123 
 hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing 1124 
 Enterobacteriaceae in Lebanon. J Clin Microbiol 43: 3309-3313.  1125 
Moreno A, Bello H, Guggiana D, Dominguez M & Gonzalez G (2008) Extended-spectrum β-1126 
 lactamases belonging to CTX-M group produced by Escherichia coli strains isolated 1127 
 from companion animals treated with enrofloxacin. Vet Microb 129: 203-208. 1128 
Mulvey MR, Bryce E, Boyd DA, Ofner-Agostini M, Land AM, Simor AE and Paton S the 1129 
 Canadian Hospital Epidemiology Committee and the Canadian Nosocomial Infection 1130 
 47 
 Surveillance Program, Health Canada (2005) Molecular characterization of cefoxitin-1131 
 resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 49: 1132 
 358-365. 1133 
Muniesa M, Garcia A, Miro E, Mirelis B, Prats G, Jofre J & Navarro F (2004) Bacteriophages 1134 
 and diffusion of β-lactamase genes. Emerg Infect Dis 10: 1134-1137. 1135 
Naas T, Zerbib M, Girlich D & Nordmann P (2003) Integration of a transposon Tn1-encoded 1136 
 inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the 1137 
 Escherichia coli chromosome. Antimicrob Agents Chemother 47: 19-26. 1138 
Nakano R, Okamoto R, Nagano N & Inoue M (2007) Resistance to gram-negative organisms 1139 
 due to high-level expression of plasmid-encoded ampC β-lactamase blaCMY-4 promoted 1140 
 by insertion sequence ISEcp1. J Infect Chemother 13: 18-23. 1141 
NARMS (2004) The US National Antimicrobial Resistance Monitoring System Reports.CDC 1142 
(center for disease control and prevention). National Antimicrobial Resistance  Monitoring 1143 
System for Enteric Bacteria (NARMS): 2004 Human Isolates Final  Report. Atlanta, 1144 
Georgia: U.S. Department of Health and Human Services, CDC. 1145 
 1146 
Naseer U, Haldorsen B, Simonsen GS & Sundsfjord A (2009) Sporadic occurrence of CMY-1147 
 2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and 1148 
 ST131 in Norway. Clin Microbiol Infect 10.1111/j.1469-0691.2009.02861.x. 1149 
Navon-Venezia S, Chmelnitsky I, Leavitt A & Carmeli Y (2008) Dissemination of the CTX-1150 
 M-25 family β-lactamases among Klebsiella pneumoniae, Escherichia coli and 1151 
 Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus 1152 
 mirabilis in Israel. J Antimicrob Chemother 62: 289-295. 1153 
Neuwirth  C, Madec S, Siebor E, Pechinot A, Duez JM, Pruneaux M, Fouchereau-Peron M, 1154 
 Kazmierczak A & Labia R (2001) TEM-89 beta-lactamase produced by a Proteus 1155 
 48 
 mirabilis clinical isolate: new complex mutant (CMT 3) with mutation in both TEM-1156 
 59 (IRT-17) and TEM-3. Antimicrob Agents Chemother 45: 3591-3594. 1157 
Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, 1158 
 Park YJ, Lavigne JP, Pitout J & Johnson JR (2008) Intercontinental emergence of 1159 
 Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob 1160 
 Chemother 61: 273-281. 1161 
Novais A, Canton R, Valverde A, Machado E, Galan JC, Peixe L, Caratolli A, Baquero F & 1162 
 Coque TM (2006) Dissemination and persistence of blaCTX-M-9 are linked to class 1 1163 
 integrons containing CR1 associated with defective transpososn derivatives from 1164 
 Tn402 located in early antibiotic resistance plasmids of IncHI2, IncP1-α and IncFI 1165 
 groups. Antimicrob Agents Chemother 50: 2741-2750.     1166 
Oliver A, Coque TM, Alonso D, Valverde A, Baquero F & Canton R (2005) CTX-M-10 1167 
 linked to a phage-related element is widely disseminated among Enterobacteriaceae in 1168 
 a Spanish hospital. Antimicrob Agents Chemother 49: 1567-1571.  1169 
Olson AB, Silverman M, Boyd DA, McGeer A, Willey BM, Pong-Porter V, Daneman N, 1170 
 Mulvey MR (2005) Identification of a progenitor of the CTX-M-9 group of extended-1171 
 spectrum beta-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob 1172 
 Agents Chemother 49: 2112-2115. 1173 
Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, et al. (2005) Spread of Escherichia 1174 
 coli strains with high-level cefotaxime and ceftazidime resistance between the 1175 
 community, long-term care facilities and hospital institutions. J Clin Microb 44:  2359-1176 
 2366. 1177 
Pai H, Kang CI, Byeon JH, Lee KD, Park WB, Kim HB, Kim EC, Oh MD, Choe KW (2004) 1178 
 Epidemiology and clinical features of bloodstream infections caused by AmpC-type-1179 
 49 
 beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 48: 1180 
 3720-3728. 1181 
Pallechi L, Bartoloni A, Fiorelli C, Mantella A, Maggio TD, Gamboa H, Gotuzzo E, Kronvall 1182 
 G, Paradisi F & Rossolini GM (2007) Rapid dissemination and diversity of CTX-M 1183 
 extended-spectrum β-lactamase genes in commensal Escherichia coli isolates from 1184 
 healthy children from low-resource settings in Latin America. Antimicrob Agents 1185 
 Chemother 51: 2720-2725.   1186 
Papagiannitsis CC, Tzouvelekis LS, Tzelepi E & Miriagou V (2007) Plasmid-encoded ACC-1187 
 4, an extended-spectrum cephalosporinase variant from Escherichia coli. Antimicrob 1188 
 Agents Chemother 51: 37-63. 1189 
Partridge SR (2007) Genetic environment of ISEcp1 and blaACC-1. Antimicrob Agents 1190 
 Chemother 51: 2658-2659. 1191 
Partidge SR & Hall RM (2003) In34, a complex In5 family class 1 integron containing orf513 1192 
 and dfrA10. Antimicrob Agents Chemother 47: 342-349.  1193 
Partridge SR & Hall RM (2005) Evolution of transposons containing blaTEM genes. 1194 
 Antimicrob Agents Chemother 49: 1267-1268.   1195 
Paterson DL & Bonomo RA (2005) Extended-spectrum β-lactamases: a clinical update. Clin 1196 
 Microb Rev 18: 657-686.  1197 
Pitout JDD & Laupland KB (2008) Extended-spectrum β-lactamase-producing 1198 
 Enterobacteriaceae: an emerging public-health concern. The Lancet 8: 159-66. 1199 
Pitout JDD, Gregson DB, Church DL & Laupland K (2007) Population-based laboratory 1200 
 surveillance for AmpC β-lactamase-producing Escherichia coli, Calgary. Emerg Infect 1201 
 Dis 13: 443-448. 1202 
 50 
Pitout JDD, Nordmann P, Laupland KB & Poirel L (2005) Emergence of Enterobacteriaceae 1203 
 producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob 1204 
 Chemother 56: 52-59. 1205 
Pitout  JDD, Gregson DB, Church DL, Elsayed S & Laupland KB (2005) Community-wide 1206 
 outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli 1207 
 strains in the Calgary health region. J Clin Microb 43: 2844-2849.  1208 
Phillipon A, Arlet G & Jacoby GA (2002) Plasmid-determined AmpC-type β-lactamases. 1209 
 Antimicrob Agents Chemother 46: 1-11. 1210 
Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones R, Nightingale C, Preston R & 1211 
 Wadell J (2004) Does the use of antibiotics in food animals pose a risk to human 1212 
 health? A critical review of published data. J Antimicrob Chemother 53: 28-52. 1213 
Poeta P, Radhouani H, Igrejas G, Gonçalves A, Carvalho C, Rodrigues J, Vinué L, Somalo S 1214 
 & Torres C (2008) Seagulls of the Berlengas Natural Reserve of Portugal as carriers of 1215 
 fecal Escherichia coli harboring CTX-M and TEM extended-spectrum beta-1216 
 lactamases. Appl Environ Microb 74: 7439-7441.  1217 
Poirel L, Naas T & Nordmann P (2008) Genetic support of extended-spectrum β-lactamases. 1218 
 Clin Microb Infect 14: 75-81. 1219 
Poirel L, Lartigue MF, Decousser JW & Nordmann P (2005a) ISEcp1B-mediated 1220 
 transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother 49: 447-1221 
 450.  1222 
Poirel L, Van de Loo M, Mammeri H & Nordmann P (2005b) Association of plasmid-1223 
 mediated quinolone resistance with extended-spectrum β-lactamase VEB-1. 1224 
 Antimicrob Agents Chemother 49: 3091-3094.  1225 
Poirel L, Le Thomas I, Naas T, Karim A & Nordmann P (2000) Biochemical sequence 1226 
 analysis of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 1227 
 51 
 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 44: 622-1228 
 632.  1229 
Poirel L, Naas T, Guibert M, Chaibi EB, Labia R & Nordmann P (1999) Molecular and 1230 
 biochemical characterization of VEB-1, a novel class A extended-spectrum β-1231 
 lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents 1232 
 Chemother 43: 573-581. 1233 
Politi L, Tassios PT, Lambiri M, Kansouzidou A, Pasiotou M, Vatopoulos AC, Mellou K, 1234 
 Legakis NJ & Tzouvelekis LS (2005) Repeated occurrence of diverse extended-1235 
 spectrum β-lactamases in minor serotypes of food-borne Salmonella enterica subsp. 1236 
 enterica. J Clin Microbiol 43: 3453-3456.   1237 
Pomba C, Fonseca JDD, Baptista BC, Correia JD & Martinez-Martinez L (2009) Detection of 1238 
 the pandemic O25-ST131 Human Virulent Escherichia coli CTX-M-15-producer 1239 
 clone harbouring the qnrB2 and aac(6’)-lb-cr genes in a dog. Antimicrob Agents 1240 
 Chemother 53:327-8. 1241 
Pongpech P, Naenna P, Taipobsakul Y, Tribuddharat C, Srifuengfung S (2008) Prevalence of 1242 
 extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in 1243 
 Escherichia coli from Thai patients and healthy adults. Southeast Asian J Trop Med 1244 
 Public Health 39: 425-433. 1245 
Poole K (2004) Resistance to β-lactam antibiotics. Cell Mol Life Sic 61: 2200-2233. 1246 
Potz NA, Hope R, Warner M, Johnson AP, Livermore DM; London & South East ESBL 1247 
 Project Group (2006) Prevalence and mechanisms of cephalosporin resistance in 1248 
 Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 58: 1249 
 320-326. 1250 
 52 
Power P, Galleni M, Conza JD, Ayala JA & Gutkind G (2005) Description of In116, the first 1251 
 blaCTX-M-2-containing complex class 1 integron found in Morganella morganii isolates 1252 
 from Buenos Aires, Argentina. J Antimicrob Chemother 55: 461-465. 1253 
Queenan AM, Jenkins S & Bush K (2001) Cloning and biochemical characterization of FOX-1254 
 5, an AmpC-type plasmid-encoded β-lactamase from a New York City Klebsiella 1255 
 pneumoniae clinical isolate. Antimicrob Agents Chemother 45: 3189-3194.  1256 
Rankin SC, Whichard JM, Joyce K, Stephens L, O’Shea K, Aceto H, Munro DS & Benson 1257 
 CE (2005) Detection of a blaSHV extended-spectrum β-lactamases in Salmonella 1258 
 enterica serovar Newport MDR-AmpC. J Clin Microb 43: 5792-5793. 1259 
Raskine L, Borrel I, Barnaud G, Boyer S, Hanau-Bercot B, Gravisse J, Labia R, Arlet G & 1260 
 Sanson-Le-Pors MJ (2002) Novel plasmid-encoded class C β-lactamase (MOX-2) in 1261 
 Klebsiella pneumoniae from Greece. Antimicrob Agents Chemother 46: 2262-2265. 1262 
Rayamajhi N, Kang SG, Lee DY, Kang ML, Lee SI, Park KY, Lee HS & Yoo HS (2008) 1263 
 Characterization of TEM-, SHV- and AmpC-type β-lactamases from cephalosporin-1264 
 resistant Enterobacteriaceae isolated from swine. Int J Food Microb 124: 183-187. 1265 
Riaño I, Moreno MA, Teshager T, Saenz Y, Dominguez L & Torres C (2006) Detection and 1266 
 characterization of extended-spectrum β-lactamases in Salmonella enterica strains of 1267 
 healthy food animals in Spain. J Antimicrob Chemother 58: 844-847.  1268 
Riaño I, Garcia-Campello M, Saenz Y, Alvarez P, Vinué L, Lantero M, Moreno MA, 1269 
 Zarazaga M & Torres C (2009) Occurence of extended-spectrum β-lactamase-1270 
 producing Salmonella enterica in northern Spain with evidence of CTX-M-9 clonal 1271 
 spread  among animals and humans. Clin Microbiol Infect 15: 292-295. 1272 
Rice LB, Eckstein EC, DeVente J & Shlaes DM (1996) Ceftazidime-resistant Klebsiella 1273 
 pneumoniae isolates recovered at the Cleveland department of Veterans Affair 1274 
 Medical Center. Clin Infect Dis 23: 118-124.  1275 
 53 
Rice LB, Willey SH, Papanicolaou, Medeiros A, Eliopoulos GM, Moellering RC & Jacoby 1276 
 GA (1990) Outbreak of ceftazidime resistance caused by extended-spectrum beta-1277 
 lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 34: 1278 
 2193-2199. 1279 
Rodriguez-Bano J, Lopez-Cerero L, Navarro MD, de Alba PD & Pascual Alvaro (2008) 1280 
 Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: 1281 
 prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62: 1282 
 1142-1149. 1283 
Rodriguez-Bano J, Alcala J, Cisneros JM, et al. (2009) Escherichia coli producing SHV-type 1284 
 extended-spectrum β-lactamase is a significant cause of community-acquired 1285 
 infection. J Antimicrob Chemother 63: 781-784. 1286 
Rodríguez MM, Power P, Radice M, Vay C, Famiglietti A, Galleni M, Ayala JA, Gutkind G 1287 
 (2004) Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible origin 1288 
 of plasmid-borne CTX-M-1-derived cefotaximases. Antimicrob Agents Chemother 48: 1289 
 4895-4897. 1290 
Romero L, Lopez L, Rodriguez-Bano J, Hernandez R, Martinez-Martinez L & Pascual A 1291 
 (2005) Long-term study of the frequency of Escherichia coli and Klebsiella 1292 
 pneumoniae isolates producing extended-spectrum β-lactamases. Clin Microbiol Infect 1293 
 11: 625-631. 1294 
Sabaté M, Navarro F, Miro E, Campoy S, Mirelis B, Barbé J & Prats G (2002) Novel 1295 
 complex sul1-type integron in Escherichia coli carrying blaCTX-M-9. Antimicrob Agents 1296 
 Chemother 46: 2656-2661. 1297 
Saladin M, Cao VTB, Lambert T, Donay JL, Herrmann JL, Ould-Hocine Z, Verdet C, Delisle 1298 
 F, Philippon A, Arlet G (2002) Diversity of CTX-M β-lactamases and their promoter 1299 
 54 
 regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol 1300 
 Lett 209: 161-168. 1301 
Schwarz S & Chaslus-Dancla E (2001) Use of antimicrobials in veterinary medicine and 1302 
 mechanisms of resistance. Vet Res 32: 201-225. 1303 
Schwarz S, Kehrenberg C & Walsh TR (2001) Use of antimicrobial agents in veterinary 1304 
 medecine and food animal production. Int J Antimicrob Chemother 17: 431-437. 1305 
Sidjabat HE, Hanson ND, Smith-Moland E, Bell JM, Gibson JS, Filippich LJ & Trott DJ 1306 
 (2007) Identification of plasmid-mediated extended-spectrum and AmpC β-lactamases 1307 
 in Enterobacter spp. isolated from dogs. J Med Microb 56: 426-434.  1308 
Shah AA, Hasan F, Ahmed S & Hameed A (2004) Extended-spectrum β-lactamases (ESBLs): 1309 
 characterization, epidemiology and detection. Crit Reviews Microbiol 30: 25-32. 1310 
Shen P, Jiang Y, Zhou Z, Zhang J, Yu Y & Li L (2008) Complete nucleotide sequence of 1311 
 pKP96, a 67850 bp multiresistance plasmid encoding qnrA1, aac(6’)-lb-cr and 1312 
 blaCTX-M-24 from Klebsiella pneumoniae. J Antimicrob Chemother 62: 1252-1256. 1313 
Shiraki Y, Shibata N, Doi Y & Arakawa Y (2004) Escherichia coli producing CTX-M-2 beta-1314 
 lactamase in cattle, Japan. Emerg Infect Dis 10: 69-75. 1315 
Sjölund M, Yam J, Schwenk J, Joyce K, Medalla F, Barzilay E & Whichard JM (2008) 1316 
 Human Salmonella infection yielding CTX-M β-lactamase, United States. Emerg 1317 
 Infect Dis 14: 1957-1959. 1318 
Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Catry B, Herman L, Haesebrouck F 1319 
 & Butaye P (2008) Diversity of extended-spectrum β-lactamases and class C β-1320 
 lactamases among cloacal Escherichia coli in Belgian broiler farms. Antimicrob 1321 
 Agents Chemother 52: 1238-1243. 1322 
Smet A,  Martel A, Persoons D, Dewulf J, Heyndrickx M, Cloeckaert A, Praud K, Claeys G, 1323 
 Catry B, Herman L, Haesebrouck F & Butaye P (2009) Comparative analysis of 1324 
 55 
 Extended-spectrum-β-lactamase (ESBL)-carrying plasmids from different members of 1325 
 Enterobacteriaceae isolated from poultry, pigs and humans: evidence for a shared β-1326 
 lactam resistance gene pool? J Antimicrob Chemother 63: 1286-1288. 1327 
Soge OO, Queenan AM, Ojo KK, Adeniyi BA & Roberts MC (2006) CTX-M-15 extended-1328 
 spectrum β-lactamase from Nigerian Klebsiella pneumoniae. J Antimicrob Chemother 1329 
 57: 24-30. 1330 
Song W, Lee H, Lee K, Jeong SH, Bae IK, Kim JS & Kwak HS (2009) CTX-M-14 and CTX-1331 
 M-15 enzymes are the dominant type of extended-spectrum β-lactamase in clinical 1332 
 isolates of Escherichia coli from Korea. J Med Microbiol 58: 261-266. 1333 
Stokes HW, Tomaras C, ParsonsY & Hall RM (1993) The partial 3’-conserved segment 1334 
 duplications in the integrons In6 from pSa and In7 from pDGO100 have a common 1335 
 origin. Plasmid 31: 39-50.  1336 
Su LH, Wu TL, Chia JH, Chu C, Kuo AJ & Chiu CH (2005) Increasing ceftriaxone resistance 1337 
 in Salmonella isolates from a university hospital in Taiwan. J Antimicrob Chemother 1338 
 55: 846-852. 1339 
Sunde M, Tharaldsen H, Slettemeas JS, Norstrom M, Caratolli A & Bjorland J (2009) 1340 
 Escherichia coli of animal origin in Norway contains a blaTEM-20-carrying plasmid 1341 
 closely related to blaTEM-20 and blaTEM-52 plamids from other European countries.  J 1342 
 Antimicrob Chemother 63: 215-223. 1343 
Taguchi M, Seto K, Yamazaki W, Tsukamoto T, Izumiya H & Watanabe H (2006) CMY-2 β-1344 
 lactamase-producing Salmonella enterica Serovar Infantis isolated from poultry in 1345 
 Japan. Jpn J Infect Dis 59: 144-146. 1346 
Tavakoli N, Commanducci A, Dodd HM, Lett MC, Albiger B & Bennet PM (2000) IS1294, a 1347 
 DNA element that transposes by RC transposition. Plasmid 44: 66-84. 1348 
 56 
Teshager T, Domínguez L, Moreno MA, Saénz Y, Torres C & Cardeñosa S (2000) Isolation 1349 
 of an SHV-12 β-lactamase-producing Escherichia coli strain from a dog with recurrent 1350 
 urinary tract infections. Antimicrob Agents Chemother 44: 3483-3484. 1351 
The Danish Integrated Antimicrobial Resistance Monitoring and Research Programme 1352 
 (DANMAP) (2006) Consumption of antimicrobial agents and occurrence of 1353 
 antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. 1354 
 Available at: http://www.danmap.org/pdfFiles/Danmap_2006.pdf. Accessed 28 1355 
 August 2008. 1356 
Tian GB, Wang HN, Zou LK, Tang JN, Zhao YW, Ye MY, Tang JY, Zhang Y, Zhang AY, 1357 
 Yang X, Xu CW & Fu YJ (2009) Detection of CTX-M-15, CTX-M-22 and SHV-2 1358 
 extended-spectrum β-lactamases (ESBLs) in Escherichia coli fecal sample isolates 1359 
 from pig farms in China. Microb Drug Res 3: 297-304. 1360 
Tian SF, Chen BY, Chu YZ, Wang S (2009) Prevalence of rectal carriage of extended-1361 
 spectrum beta-lactamase-producing Escherichia coli among elderly people in 1362 
 community settings in China. Can J Microbiol 54: 781-785. 1363 
Toleman MA, Bennett PM & Walsh TR (2006a) Common regions e.g. orf513 and antibiotic 1364 
 resistance: IS91-like elements evolving complex class 1 integrons. J Antimicrob 1365 
 Chemother 58: 1-6.  1366 
Toleman MA, Bennett PM & Walsh TR (2006b) ISCR elements: novel gene-capturing 1367 
 systems of the 21st century? Microbiol Mol Biol Rev 70: 296-316.  1368 
Toleman MA, Rolston K, Jones RN & Walsh TR (2003) Molecular and biochemical 1369 
 characterization of OXA-45, an extended-spectrum class 2d’ beta-lactamase in 1370 
 Pseudomonas aeroginosa. Antimicrob Agents Chem 47: 2859-2893. 1371 
Vahaboglu H, Fuzi M, Cetin S, Gundes S, Ujhelyi E, Coskunkan F & Tansel O (2001) 1372 
 Characterization of extended-spectrum β-lactamase (TEM-52)-producing strains of 1373 
 57 
 Salmonella enterica serovar Typhimurium with diverse resistance phenotypes. J Clin 1374 
 Microbiol 39: 791-793. 1375 
Valverde A, Canton R, Galan JC, Nordmann P, Baquero F & Coque TM (2006) In117, an 1376 
 unusual In0-like class 1 integron containing CR1 and blaCTX-M-2 and associated with a 1377 
 Tn21-like element. Antimicrob Agents Chemother 50: 799-802.  1378 
Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R (2004) 1379 
 Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-1380 
 lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J 1381 
 Clin Microbiol 42: 4769-4775 1382 
Verdet C, Arlet G, Barnaud G, Lagrange PH & Philippon A (2000) A novel integron in 1383 
 Salmonella enterica Serovar Enteritidis, carrying the blaDHA-1 gene and its regulator 1384 
 gene ampR, originated from Morganella morganii. Antimicrob Agents Chemother 44: 1385 
 222-225. 1386 
Vignoli R, Cordeiro NF, Garcia V, Mota MI, Betancor L, Power P, Chabalgoity A, Schelotto 1387 
 F, Gutkind G & Ayala JA (2006) New TEM-derived extended-spectrum β-lactamase 1388 
 and its genomic context in plasmids from Salmonella enterica Serovar Derby isolates 1389 
 from Uruguay. Antimicrob Agents Chemother 50: 781-784.  1390 
Vinué L, Sáenz Y, Martínez S, Somalo S, Moreno MA, Torres C, Zarazaga M (2009) 1391 
 Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia 1392 
 coli isolates from healthy humans in Spain. Clin Microbiol Infect 10.1111/j.1469-1393 
 0691.2009.02803.x  1394 
Vo ATT, Duikeren EV, Fluit AC & Gaastra W (2007) Characterization of extended-spectrum 1395 
 cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates from 1396 
 horses. Vet Microb 124: 248-255.  1397 
 58 
Walsh TR (2008) Clinically significant carbapenamases: an update. Curr Opinio Infect Dis 1398 
 21: 367-371. 1399 
Watson ADJ & Rosin E (2000) Antimicrobial drug use in dogs and cats. In Antimicrobial 1400 
 Therapy in Veterinary Medicine, 3rd ed., (Prescott JF, Baggot JD & Walker RD, eds), 1401 
 pp. 537-575. Iowa State University Press, USA.  1402 
Weill FX, Demartin M, Fabre L & Grimont PAD (2004) Extended-spectrum-β-lactamase 1403 
 (TEM-52)-producing strains of Salmonella enterica of various serotypes isolated in 1404 
 France. J Clin Microb 42: 3359-3362.  1405 
Weill FX, Lailler R, Praud K, Kerouanton A, Fabre L, Brisabois A, Grimont PAD & 1406 
 Cloeckaert A (2004) Emergence of extended-spectrum β-lactamase (CTX-M-9)-1407 
 producing multiresistant strains of Salmonella enterica Serotype Virchow in poultry 1408 
 and humans in France. J Clin Microb 42: 5767-5773.  1409 
Whichard JM, Joyce K, Fey PD, Nelson JM, Angulo FJ & Barrett TJ (2005) β-lactam 1410 
 resistance and Enterobacteriaceae, United States. Emerg Infect Dis 11: 1464-1466.  1411 
Winokur PL, Bruegegemann A, DeSalvo DL, Hoffmann L, Apley MD, Uhlenhopp EK, 1412 
 Pfaller MA & Doern GV (2000) Animal and human multidrug-resistant Salmonella 1413 
 isolates expressing a plasmid-mediated CMY-2 AmpC β-lactamase. Antimicrob 1414 
 Agents Chemother 44: 2777-2783.  1415 
Winokur PL, Vonstein DL, Hoffman LJ, Uhlenhopp EK & Doern GV (2001) Evidence for 1416 
 transfer of CMY-2 AmpC β-lactamase plasmids between Escherichia coli and 1417 
 Salmonella isolates from food animals and humans. Antimicrob Agents Chemother 45: 1418 
 2716-2722.  1419 
Woodford N, Reddy S, Fagan EJ, Hill RLR, Hopkins KL, Kaufmann ME, Kistler J, Palepou 1420 
 MFI, Pike R, Ward ME, Chessbrough J & Livermore DM (2007) Wide geographic 1421 
 59 
 spread of diverse acquired AmpC beta-lactamases among Escherichia coli and 1422 
 Klebsiella spp. in the UK and Ireland. J Antimicrob Chemother 59: 102-105. 1423 
Wu SW, Dornbush K, Kronvall G & Norgren M (1999) Characterization and nucleotide 1424 
 sequence of a Klebsiella oxytoca cryptic plasmid encoding a CMY-type β-lactamase: 1425 
 confirmation that the plasmid mediated cephamycinase originated from the 1426 
 Citrobacter freundii AmpC β-lactamase . Antimicrob Agents Chemother 43: 1350-1427 
 1357. 1428 
Yan JJ, Hong CY, Ko WC, Chen YJ, Tsai SH, Chuang CL, Wu JJ (2004) Dissemination of 1429 
 blaCMY-2 among Escherichia coli isolated from food, animals, retail ground meats and 1430 
 humans in Southern Taiwan. Antimicrob Agents Chemother 48: 1353-1356. 1431 
Yu WL, Chen SC, Hung SW, Chuang YC, Chung JG, Chen IC & Wu LT (2006) Genetic 1432 
 association of blaSHV-5 with transposable elements IS26 and IS5 in Klebsiella 1433 
 pneumoniae from Taiwan. Clin Microbiol Infect 12: 806-808. 1434 
Zaidi MB, Leon V, Canche C, Perez C, Zhao S, Hubert SK, Abbott J, Blickenstaff K & 1435 
 McDermott PF (2007) Rapid and widespread dissemination of multidrug-resistant 1436 
 blaCMY-2  Salmonella Typhimurium in Mexico. J Antimicrob Chemother 60: 398-401. 1437 
Zhao S, White DG, Friedman SL, Glenn A, Blickenstaff K, Ayers SL, Abbott JW, Hall-1438 
 Robinson E & McDermott PF (2008) Antimicrobial resistance in Salmonella enterica 1439 
 Serovar Heidelberg isolates from retail meats, including poultry, from 2002 to 2006. 1440 
 Appl Environ Microb 74: 6656-6662. 1441 
Zhanel GG, DeCorby M, Laing N, et al. (2008) Antimicrobial-resistant pathogens in intensive 1442 
 care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) 1443 
 Study,  2005-2006. Antimicrob Agents Chemother 52: 1430-1437. 1444 
 1445 
 60 
Table 1. β-lactams used in veterinary and human medicine (Guardabassi et al., 2008; Hammerum & Heuer, 2009; Hornish & Kotarski, 2002) 1446 
β-lactams Spectrum of activity Veterinary medicine Human medicine 
Penicillins are mainly active against Gram-positive 
bacteria. Aminopenicillins are also active 
against Gram-negative bacteria. 
 
ampicillin, amoxicillin, 
benzylpenicillin, cloxacillin, 
hetacillin 
penicillin, ampicillin, amoxicillin 
Penicillin-β-lactamase inhibitor 
combinations 
exhibit negligible antimicrobial activity. 
Their sole purpose is to prevent the 
inactivation of β-lactam antibiotics and, as 
such, they are co-administrated mostly 
with penicillins 
 
amoxicillin-clavulanate amoxicillin-clavulanate, piperacillin-
tazobactam 
First generation cephalosporins are moderate spectrum agents. They are 
effective alternatives for treating 
staphylococcal and streptococcal 
infections. 
 
cepadroxil, cefapirin, cephalexin Cefalozin 
Second generation cephalosporins have a greater Gram-negative spectrum 
while retaining some activity against 
Gram-positive bacteria. 
 
cefaclor, cefamandole, cefonicid, 
ceforanide, cefuroxime 
cefuroxime, cefoxitin 
Third generation cephalosporins have a broad spectrum of activity and 
further increased activity against Gram-
negative organisms. 
 
cefovecin, cefpodoxim, ceftiofur ceftriaxone, cefotaxime, ceftazidime 
Fourth generation cephalosporins have the broadest activity both against 
Gram-negative and Gram-positive bacteria. 
 
cefquinome Cefepime 
Monobactams have a strong activity against susceptible 
Gram-negative bacteria, but no useful 
activity against Gram-positive bacteria or 
anaerobes. 
 
not in use Aztreonam 
Carbapenems have a broad spectrum of activity against 
aerobic and anaerobic Gram-positive and 
Gram-negative bacteria. 
imipenem, meropenema imipenem, meropenem 
 61 
a Use only in the case of life-threatening infections and when susceptibility tests have shown resistance to all other antimicrobials except 1447 
carbapenems. 1448 
 1449 
 1450 
 1451 
 1452 
 1453 
 1454 
 1455 
 1456 
 1457 
 1458 
 1459 
 1460 
 1461 
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Table 2. Use of β-lactams as the first or second choice for the treatment of diseases in swine, cattle, poultry, horses, and cats & dogs (modified 1462 
from Guardabassi et al., 2008) 1463 
Animal Clinical indication β-lactam use (first choice) β-lactam use (second choice) 
swine necrotic enteritis penicillins  
 respiratory/systemic disease penicillins, ceftiofur  
cattle neonatal septicemiae  third (ceftiofur) or fourth (cefquinome) generation 
cephalosporins 
 salmonellosis ceftriaxone  
 calf diarrhoea ampicillin, amoxicillin, amoxicillin-clavulanic acid  
 septic arthritis ampicillin, amoxicillin third or fourth generation cephalosporins  
 foot rotb ampicillin  
 metritisb ampicillin, penicillin  
 mastitis penicillin third or fourth generation cephalosporins 
poultry dysbacteriosis benzylpenicillins  
 collibacilosis ampicillin, amoxicillin  
 Ornithobacterium rhinotracheale 
infection 
ampicillin, amoxicillin  
 fowl cholera ampicillin, amoxicillin  
 Riemerella  anatipestifer infections ampicillin, amoxicillin  
 erysipelas penicillins  
horses clostridial myostitis penicillins  
 63 
 pigeon fever penicillins  
 osteomyelitis penicillins Ceftiofur 
 septic arthritis penicillin Ceftiofur 
 wounds penicillina Ceftiofur 
 cystitis penicillin, ampicillin ceftiofur  
 pyelonephritis ampicillin Ceftiofur 
 endocarditis, pericarditis penicillina Ceftiofur 
 bacterial meningitis penicillina Ceftiofur 
 listeriosis penicillin, ampicillin Ceftiofur 
 cellulitis ceftiofur  
 neonatal septicemiae penicillina third generation cephalosporins 
cats & 
dogs 
 reccurent pyoderma amoxicillin-clavulanic acid, first generation 
cephalosporins 
 
 skin wounds cefotaxime, cephalexin  
 cystitis aminopenicillins  amoxicillin-clavulanic acid, cephalosporins 
 acute peritonitis cefoxitin, cefotetan  
 pneumoniae amoxicillin-clavulanic acid, cephalosporins  
 osteomyelitis amoxicillin-clavulanic acid, cephalosporins  
 leptospirosis penicillin G, amoxicillin  
a in combination with gentamicin; bceftiofur is used as last choice  1464 
 64 
Table 3. Known blaTEM gene-transposon associations 1465 
bla gene Transposon-like structure Reference 
blaTEM-1a Tn3 Partidge & Hall, 2005 
 blaTEM-1b Tn2 Partridge & Hall, 2005 
blaTEM-2 Tn1 Partidge & Hall, 2005 
blaTEM-3 Tn1 Mabilat et al., 1992 
blaTEM-10 Tn2 Bradford et al., 1994 
blaTEM-12 Tn2 Bradford et al., 1994 
blaTEM-15 Tn801 (Tn3-like) Chouchani et al., 2007 
blaTEM-20 Tn3 Sunde et al., 2009 
blaTEM-21 Tn801 (Tn3-like) Dubois et al., 2005 
blaTEM-52 Tn3 Cloeckaert et al., 2007 
blaTEM-67 Tn1 Naas et al., 2003 
blaTEM-121 Tn3 Dubois et al., 2002 
blaTEM-144 Tn2 Vignoli et al., 2006 
 1466 
 1467 
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Supplementary file 1. Presence of Enterobacteriaceae producing broad-spectrum β-lactamases in food-producing animals (per animal group, 1472 
ESBL-producing Enterobacteriaceae are listed first followed by the AmpC β-lactamase-producing Enterobacteriaceae)  1473 
Healthy animals 
Animal Percentage of 
samples in which β-
lactamases were 
found to be present 
(Total number of 
samples tested) 
Proportion (as %) of 
positive samples in 
which each type of β-
lactamase was found 
Species Year of isolation Country Reference 
poultry 17.5 (40) TEM-52 (80), CTX-M-
1 (7), SHV-2 (13) 
E. coli, K. pneumoniae 1998-2004 Portugal Machado et al., 2008 
 not specified TEM-52 Salmonella spp. 2001-2005 Belgium Cloeckaert et al., 2007 
 not specified TEM-52 Salmonella spp. 2001-2002 The Netherlands Hasman et al., 2005 
 40.1 (76) TEM-52 (83), CTX-M-
14 (9.5), CTX-M-32 
(7.5) 
E. coli 2004 Portugal Costa et al., 2009 
 10.7 (489) TEM-52 (14), TEM-106 
(2), CTX-M-1 (20), 
CTX-M-2 (8), CTX-M-
14 (6), CTX-M-15 (2) 
E. coli 2007 Belgium Smet et al., 2008 
 11 (112) CTX-M-1 E. coli 2005 France Girlich et al., 2007 
 6.4 (38) CTX-M-8(10), CTX-M-
14 (30), SHV-5 (10) 
E. coli Not specified Tunesia Jouini et al., 2007 
 0.2 (2747) CTX-M-2 (17), CTX-
M-14 (5.5) 
E. coli 1999-2002 Japan Kojima et al., 2005 
 0.7 (556) CTX-M-9 Salmonella spp. 1999-2004 Spain Riaño et al., 2006 
 1.6 (120) CTX-M-14 (20), SHV-
12 (20) 
E. coli 2000-2001 Spain Briñas et al., 2003 
 0.6 (2162) SHV-12 Salmonella spp. 2005-2006 Italy Chiaretto et al., 2008 
 0.8 (120) CMY-2 (20) E. coli 2000-2001 Spain Briñas et al., 2003 
 0.1 (8426) CMY-2 Salmonella spp. 1994-1999 Canada Allen & Poppe, 2002 
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 0.3 (2747) CMY-2 (44) E. coli 1999-2002 Japan Kojima et al., 2005 
 6.9 (83) CMY-2 Salmonella sp. 2004-2005 Japan Taguchi et al., 2006 
 10 (489) CMY-2 (41) E. coli 2007 Belgium Smet et al., 2008 
 3.1 (32) CMY-2 E. coli Not specified Taiwan Yan et al., 2004 
 10 (10119) CMYa Salmonella sp. 2002-2006 United States Zhao et al., 2008 
 1.6 (120) Mutation promoter 
region AmpC (40) 
E. coli 2000-2001 Spain Briñas et al., 2003 
 0.3 (2747) Mutation promoter 
region AmpC (44) 
E. coli 1999-2002 Japan Kojima et al., 2005 
 4 (76) Mutation promoter 
region AmpC (9) 
E. coli 2004 Portugal Costa et al., 2009 
cattle 2.6 (607) CTX-M-1(84), CTX-M-
14 (8), SHV-12 (8) 
E. coli 2006 France Madec et al., 2008 
 6.4 (38) CTX-M-1 (60) E. coli Not specified Tunesia Jouini et al., 2007 
 1.5 (270) CTX-M-2 E. coli 2000-2001 Japan Shiraki et al., 2004 
 37 (297) CTX-Ma E. coli 2004 United Kingdom Liebana et al., 2006 
 0.01 (8426) CMY-2 Salmonella spp. 1994-1999 Canada Allen & Poppe, 2002 
 88.5 (122) CMY-2 E. coli 2003 United States Donaldson et al., 2006 
 27.7 (297) Mutation promotor 
region AmpC 
E. coli 2004 United Kingdom Liebana et al., 2006 
pigs 6.6. (212) CTX-M-15 (35), CTX-
M-22 (57), SHV-2 (8) 
E. coli 2002-2007 China Tian et al., 2009 
 0.2 (436) SHV-12 Salmonella spp. 1999-2004 Spain Riaño et al., 2006 
 2.6 (35) SHV-12 Citrobacter Freundi 1998-2004 Portugal Machado et al., 2008 
 2.4 (86) CMY-2 E. coli Not specified Canada Kozak et al., 2009 
 7.4 (280) CMY-2 Salmonella sp. 2000-2005 Mexico Zaidi et al., 2007 
 30 (30) CMY-2 E. coli Not specified Taiwan Yan et al., 2004 
Sick animals 
cattle 2.4 (3984) CMY-2 Salmonella spp. 2000-2004 United States Freye et al., 2008 
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 0.6 (2252) AmpCa Salmonella spp. 1999-2001 United States Gupta et al., 2003 
 77 (32) Mutation promoter 
region AmpC 
E. coli 1996 United States Bradford et al., 1999 
 0.03 (16200) Mutation promoter 
region AmpC 
E. coli 2002 United Kingdom Liebana et al., 2004 
 6.2 (657) CTX-M-1 (70), CTX-
M-14 (18), CTX-M-15 
(6), TEM-126 (6) 
E. coli 2006 France Madec et al., 2008 
pigs 5.3 (156) TEM-20 (22), TEM-52 
(11), SHV-28 (22), 
SHV-33 (22) 
E. coli, K. pneumoniae 1999-2006 Korea Rayamajhi et al., 2008 
 8.4 (156) CMY-2 (11), DHA-
1(33) 
K. pneumoniae 1999-2006 Korea Rayamajhi et al., 2008 
cattle & pigs 20.7 (535) CMY-2 E. coli, Salmonella 1998-1999 United States Winokur et al., 2000 
anot genotypically characterized 1474 
 1475 
 1476 
 1477 
 1478 
 1479 
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 1481 
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Supplemetary file 2. Presence of Enterobacteriaceae producing broad-spectrum β-lactamases in companion animals (per animal group, ESBL-1484 
producing Enterobacteriaceae are listed first followed by the AmpC β-lactamase-producing Enterobacteriaceae)  1485 
Healthy animals 
Animal Percentage of 
samples in which 
β-lactamases were 
found to be 
present (Total 
number of 
samples tested) 
Proportion (as %) of 
positive samples in 
which each type of β-
lactamase was found 
 
Species Year of isolation Country Reference 
dogs 10.4 (75) TEM-52 (75), CTX-
M-1 (25) 
E. coli Not specified Portugal Costa et al., 2004 
 20 (72) CTX-M-1 (7.5) E. coli 2001-2003 Italy Carattoli et al., 2005 
 14.3 (70) CTX-M-1 (40), CTX-
M-14 (40), PER-2 (50) 
E. coli 2006 Chile Moreno et al., 2007 
 7 (72) CMY-2 (5) E. coli 2001-2003 Italy Carattoli et al., 2005 
cats 5.7 (70) CTX-M-1 (100), PER-
2 (75) 
E. coli 2006 Chile Moreno et al., 2007 
Sick animals 
dogs 19.4 (72) CTX-M-1 (52), SHV-
12 (20) 
E. coli 2001-2003 Italy Carattoli et al., 2005 
 4.2 (72) SHVa E. coli Not specified Portugal Feria et al., 2002 
 11 (72) AmpCa E. coli Not specified Portugal Feria et al., 2002 
 1.6 (61) CTX-M-15 (33) E. coli 2004-2006 Portugal Pomba et al., 2008 
 3.2 (61) CMY-2 (66) E. coli 2004-2006 Portugal Pomba et al., 2008 
 1.4 (72) CMY-2 (5) E. coli 2001-2003 Italy Carattoli et al., 2005 
 4.7 (780) CMY-7 E. coli 2000-2001 Australia Sidjabat et al., 2006 
cats 2.7 (72) CTX-M-1 (10.5) E. coli 2001-2003 Italy Carattoli et al., 2005 
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horses 0.3 (1347) CTX-M-1 (45) E. coli, K. pneumoniae 2003-2005 The Netherlands Vo et al., 2007 
 0.4 (1347) CMY-2 (55) E. coli, K. pneumoniae 2003-2005 The Netherlands Vo et al., 2007 
anot genotypically characterized 1486 
 1487 
 1488 
 1489 
 1490 
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 1493 
 1494 
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Supplementary file 3. Presence of E. coli producing broad-spectrum β-lactamases in wild animals in Portugal and France (Costa et al., 2006; 1500 
Poeta et al., 2008; Bonnedahl et al., 2009) 1501 
Animal Percentage of samples in which β-lactamases 
were found to be present (Total number of 
samples tested) 
Proportion (as %) of positive samples in 
which each type of β-lactamase was found  
Year of isolation 
deer, owl, birth of prey, fox 19.2 (72) TEM-52 (44), CTX-M-1(11), SHV-12 (11), 
CTX-M-14 (34) 
2003-2004 
Seagulls 19.1 (57) TEM-52 (72), CTX-M-1(9), CTX-M-14 (9), 
CTX-M-32 (9) 
2007 
yellow-legged gulls 9.4 (90) CTX-M-1 (53), CTX-M-15 (6), TEMa(29), 
SHVb(12) 
Not specified 
anot genotypically characterized 1502 
 1503 
 1504 
 1505 
 1506 
 1507 
 1508 
 1509 
 1510 
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Supplementary file 4. Occurrence of  faecal carriage of broad-spectrum β-lactamase-producing Enterobacteriaceae in healthy humans 1513 
worldwide 1514 
Species Percentage of healthy 
human subjects tested in 
which β-lactamase was 
found to be present (Total 
number of healthy human 
subjects tested) 
Proportion (as %) of positive 
healhy humans tested in which 
each type of β-lactamase was 
found  
Year of isolation Location Reference 
E. coli, K. pneumoniae 22 (54) CTX-M-9 (1.9), CTX-M-14 (13), 
CTX-M-24 (3.7), CTX-M-38 (3.7) 
2002 China Ho et al., 2008 
E. coli 3.3 (1321)b CTX-M-3 (6.7), CTX-M-9 (60), 
CTX-M-14 (6.7), CTX-M-15 
(6.7), SHV-12 (13.3), PERa (6.7) 
2003 Spain Miro et al., 2005 
E. coli, Klebsiella 
pneumoniae, 
Enterobacter cloaca 
Citrobacter freundii 
30.8 (382) CTX-M-15 (83), SHV-5 (17) 2003 Lebanon Moubareck et al., 2005 
E. coli 0.3 in 1991 (849), 11.8 (400) 
in 2003 b 
TEM-4 (7.1), TEM-52 (3.6), 
CTX-M-10 (3.6), SHV-2 (3.6), 
SHV-12 (25), CTX-M-9 (21.4), 
CTX-M-14 (32.1) 
1991 and 2003 Spain Valverde et al., 2004 
E. coli 0.7 in 1991 (849), 5.5 in 2003 
(400)  c 
CTX-M-9 types (62.5), SHV-12 
(31.2) 
1991 and 2003 Spain Valverde et al., 2004 
E. coli 31 (159)d CTX-M (47.5), SHV (52.5)a 2005-2006 Spain Rodriguez-Baño et al., 2008 
E. coli 68 (53)b CTX-M (66.6), SHV (33.3)a 2005-2006 Spain Rodriguez-Baño et al., 2008 
E. coli 0.1 in 2002 (3174), 1.7 in 
2005 (54) 
CTX-M-2 (32), CTX-M-14 (16), 
CTX-M-15 (28), CTX-M-24 (8), 
CTX-M-56 (4), SHV-2 (2), SHV-
12 (2) 
2002 and 2005 Latin- America Pallechi et al., 2007 
E. coli, K. pneumoniae 13.1(426) Not specified Not specified Saudi Arabia Kader et al., 2007 
E. coli 7.0 (270) CTX-M-14 (58), CTX-M-22 (15), 
CTX-M-79 (22), CTX-M-24 (5) 
Not specified China Tian et al., 2009 
E. coli 0.6 (332) CTX-M-15 2006 France Leflon-Guibout et al., 2008 
E. coli 4.2 (120) Not specified Not specified Thailand Pompech et al., 2008 
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E. coli 6.7 (105) CTX-M-14 (28.5), CTX-M-1 
(28.5), CTX-M-32 (14.3), CTX-
M-8 (14.3), TEM-52 (14.3) 
2007 Spain Vinué et al., 2009 
E. coli 3.2 (63) CMY-2 2003 Japan Kaneko et al., 2007 
anot genotypically characterized, b hospitalized patients, c outpatients and d non-patients 1515 
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Supplementary file 5. Population studies of broad-spectrum β-lactamase-producing human pathogens worldwide  1530 
Species Percentage of 
samples in which β-
lactamase was 
found to be present 
(Total number of 
samples tested) 
Proportion (as %) of 
positive samples in 
which each type of β-
lactamase was found  
 
Year of isolation Type of infection Location Reference 
ESBLs 
K. pneumoniae 6 in 1993, 28 in 
1994 (not specified) 
TEM-typea 1993-1994 Not specified Hospital, USA 
 
Rice et al., 1996 
E. aerogens 14 (260)  TEM-24 (86), TEM-3 
(14) 
1994-1997 Not specified 21 different hospitals 
in Belgium   
De Gheldre et al., 
2001 
Enterobacteriaceae 12 (259) SHV-12 1995-1998 Urinary tract 
infections, 
bacteraemia 
Hospital, Cameroon Gangoué-Piéboji et 
al., 2005 
K. pneumoniae 36.1 (678) Not specified 1998-1999  Urinary tract 
infections 
Hospital, South 
Africa 
Bell et al., 2002 
E. coli, K. pneumoniae, 
Proteus mirabilis, 
Enterobacter aerogens 
1.5 (2599) TEM-3 (2), TEM-15 (5), 
TEM-19 (2), TEM-21 
(23), TEM-24 (64), CTX-
M-1 (2), SHV-44 (2) 
1999 Urinary tract 
infections, 
bacteraemia, wounds 
Hospital, France Arpin et al., 2003 
E. coli 0.3 (not specified) CTX-M-9 1996-1999 Bacteraemia, urinary 
tract infections, 
wounds 
Hospital, Spain Garcia et al., 2005 
E. coli 12 (not specified) CTX-M-2 (80), CTX-M-
39 (15), SHV-5 (5), 
SHV-12 (10), TEM-133 
(10) 
2000 Not specified Hospital, Israel Chmelnitsky et al., 
2005 
P. mirabilis 13.1 (99) SHV-5 (14), CTX-M-13 
(57), CTX-M-14 (21), 
TEM-11 (7) 
1999-2002 Bactaeremia Hospital, China Ho et al., 2005 
E. coli, K. pneumoniae 5.7 (563) CTX-M-9 (1), CTX-M-
14 (38), SHV-2 (1), 
SHV-4 (10), SHV-12 
(43), TEM-4 (4), TEM-
20 (8), TEM-53 (1) 
1995-2003 Bacteraemia, urinary 
tract infections, 
respiratory tract 
infections 
Not specified, Spain Romero et al., 2005 
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E. coli 0.3 (20258) CTX-M-typesa 1999-2003 Mainly urinary tract 
infections 
Hospital and 
community, Italy 
Brigante et al., 2005 
E. coli  1.4 (1700) CTX-M-9 (12), CTX-M-
14 (41), CTX-M-32 (3), 
TEM-52 (6), SHV-12 (9) 
2002-2003 Mainly urinary tract 
infections   
Hospital, Spain Briñas et al., 2005 
E. coli 91 (122) CTX-M-1 (1), CTX-M-3 
(2), CTX-M-9 (36), 
CTX-M-14 (22), CTX-
M-15 (2), CTX-M-32 (4), 
SHV-12 (31), SHV-2 (5), 
TEM-116 (4), TEM-52 
(2), TEM-4 (1)  
2002-2003 Urinary tract 
infections 
Community, Spain Rodriguez-Bano et 
al.,2009 
K. pneumoniae 31.3 (96) CTX-M-15 2002-2003 Urinary tract 
infections 
Community, Nigeria Soge et al., 2006 
E. coli, K. Pneumoniae 87.3 (362) E. coli: CTX-M-14 (44), 
CTX-M-15 (37), CTX-
M-27 (1), CTX-M-40 
(0.5), CTX-M-55 (17.5) 
K. pneumoniae: CTX-M-
3 (3), CTX-M-14 (52), 
CTX-M-15 (39), CTX-
M-27 (1), CTX-M-55 (5) 
2004-2005 Urinary tract 
infections 
Hospital, Thailand Kiratisin et al., 2008 
E. coli 17 (163) CTX-M-15 2006 Urinary tract 
infections 
Hospital, Italy 
 
Carattoli et al., 2008 
K. pneumoniae, E. 
aerogenes 
11.4 (6121, K. 
Pneumoniae) 
47.7 (2353, E. coli) 
Not specified Not specified Not specified Hospital, France Albertini et al., 2002 
Salmonella spp. 0.03 (3027) CTX-M-14 (12.5) 1999-2002 Salmonellosis Hospital, Taiwan Li et al., 2005 
Salmonella spp. 15.6 (160) TEM-63 (31), TEM-131 
(38), SHV-12 (31) 
2002-2003 Salmonellosis 13 different hospitals 
in South Africa 
Kruger et al., 2004 
Salmonella spp. 5.6 (1864) CTX-M-typea 2003 Not specified U.S. public health 
laboratories  
Sjölund et al., 2008 
Salmonella spp. 0.4 (1233) CTX-M-9 (60), CTX-M-
10 (20), SHV-2 (20) 
2000-2004 Salmonellosis 2 hospitals, Spain Riaño et al., 2009 
E. coli 66 (181) CTX-M-14 (7.5), CTX-
M-15 (91.5), CTX-M-32 
(1) 
2004-2006 Urinary tract 
infections, wounds, 
bacteraemia 
Hospital and 
community, Portugal 
Mendonça et al., 2007 
E. coli 0.8 (75) CTX-M-14 (92), CTX- Not specified Urinary tract Community, USA Hanson et al., 2008 
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M-15 (8) infections 
K. pneumoniae 0.9 (14) CTX-M-14 (50), SHV-
like (50) 
Not specified Urinary tract 
infections 
Community, USA Hanson et al., 2008 
E. coli 3.5 (536) CTX-M-1 (5), CTX-M-2 
(10), CTX-M-9 (5), 
CTX-M-14 (5), CTX-M-
15 (75) 
2005-2006 Respiratory tract 
infections, 
bacteraemia, urinary 
tract infections 
Health Care Centers, 
Canada 
Zhanel et al., 2007 
E. coli 14.2 (576) CTX-M-3 (12), CTX-M-
9 (2), CTX-M-12 (1), 
CTX-M-14 (39), CTX-
M-15 (33), CTX-M-22 
(2) CTX-M-27 (1), CTX-
M-57(2) 
2007 Urinary tract 
infections, wounds, 
bacteraemia  
Hospital, Korea Song et al., 2009 
AmpC β-lactamases 
E. coli 5.5 (109) Mutations ampC 
promotor 
Not specified Urinary tract 
infections 
Hospital, Sweden Bergstörm & 
Normark, 1979 
E. coli 0.7 (29323) Mutations ampC 
promotor 
2000 Not specified Hospital, Canada Mulvey et al., 2005 
E. coli 4.1 (109) Mutations ampC 
promotor 
2001 Mainly urinary tract 
infections 
University Hospital, 
Rio de Janeiro, Brazil 
Da Silva Dias et al., 
2008 
E. coli 0.5 (1700) Mutations ampC 
promotor (24) 
2002-2003 Mainly urinary tract 
infections  
Hospital, Spain Briñas et al., 2005 
E. coli 7.1 (574) Mutations ampC 
promotor 
2004 Not specified Hospitals in Londen 
and South East 
England 
Potz et al., 2006 
E. coli 0.6 (2800) Mutations ampC 
promotor 
2006 Urinary tract 
infections, septicaemia  
Hospital, France Mammeri et al., 2008 
Salmonella spp. 0.1 (4093) CMY-2 1996-1998 Salmonellosis U.S. community 
health departments  
Dunne et al., 2000 
Salmonella spp. 0.6 (320) CMY-2 1998 Salmonellosis Iowa State Hygienic 
Laboratory (U.S.) 
Winokur et al., 2000 
Non-typhi Salmonella 
spp. 
3.2 (1378) CMY 2000 Salmonellosis U.S. state and local 
public health 
laboratories 
Whichard et al., 2005 
Non-typhi Salmonella 
spp. 
0.2 (3027) CMY-2 (87.5) 1999-2002 Salmonellosis Mackay Memorial 
Hospital, Taiwan 
Li et al., 2005 
Non-typhi Salmonella 
spp.  
1.9 (160) CMY-2 2002-2003 Salmonellosis  13 different hospitals 
in South Africa 
Kruger et al., 2004 
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Salmonella spp. 8.4 (106) CMY-2 (67), CMY-4 
(11), DHA-1 (22) 
1999-2003 Salmonellosis Health Protection 
Agency, United 
Kingdom 
Batchelor et al., 2005 
Salmonella spp. 0.6 (3635) CMY-2 1999-2003 Salmonellosis Hospital, Taiwan Su et al., 2005 
E. coli 2.6 (2133) LAT-3, LAT-4 1996 Active infection Hospital, Greece Gazouili et al., 1998 
E. coli 0.6 (1017) CMY-2 1998-2000 Urinary tract 
infections, 
bacteraemia 
Hospital, USA Winokur et al., 2001 
K. pneumoniae 13.2 (408) ACT-1, DHA-1, FOX-5, 
CMY-2 
1996-2000 Not sp<ecified 24 different hospitals 
in 18 states of the 
USA 
Moland et al., 2002 
E. coli 0.09 (29323) CMY-2 1999-2000 Not specified 12 different hospitals 
in Canada 
Mulvey et al., 2005 
K. pneumoniae 7.2 (389) DHA-1 (50), CMY-1-like 
(50) 
1998-2002 Bacteraemia Seoul National 
University Hospital, 
Seoul, South Korea 
Pai et al., 2004 
E. coli 0.1 (1700) CMY-2 (6) 2002-2003 Mainly urinary tract 
infection 
Hospital, Spain Briñas et al., 2005 
E. coli 24 (103) CMY-2 (80), CMY-7 
(16), CMY-21 (4) 
1995-2003 Not specified Health Protection 
Agency, London, 
United Kingdom 
Hopkins et al., 2006a 
E. coli 0.16 (369) CMY-2 2000-2003 Not specified Calgary Health 
Region, Canada 
Pitout et al., 2007 
E. coli, K. pneumoniae 2.8 (1935) DHA-1 (76), CMY-2 
(24) 
2003-2005 Not specified Hospital, Shangai, 
China 
Li et al., 2008 
E. coli, Klebsiella spp. 49 in E. coli and 55 
in Klebsiella (173) 
CIT-type (89), ACC-
types (21), FOX (16), 
DHA (4)a 
Not specified Not specified Hospital, UK and 
Ireland  
Woodford et al., 2007 
Enterobacteriaceae 4.9 (3217) Not specified  2006-2007 Not specifeid University Hospital, 
Basel, Switzerland 
Adler et al., 2008 
anot genotypically characterized 1531 
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Figure legends  1532 
Fig. 1: Modular schematic structure of the backbones of mobile genetic elements containing 1533 
ESBL genes. (a) A blaTEM-52-carrying Tn3-like transposon  (inverted repeats, vertical black 1534 
rectangles) (Cloeckaert et al., 2007). (b) A Tn2-like transposon harbouring the blaTEM-144 gene 1535 
(Rom protein gene, horizontal black rectangles) (Vignoli et al., 2006). (c) A blashv-5 gene, 1536 
which was found together with seven other co-lineair genes (ΔigBM, fucA, ygbK, ygbJ and 1537 
ygbL) originating from K. pneumoniae and flanked by two IS26 elements inserted in the same 1538 
orientation (Miriagou et al., 2005). (d) An ISEcp1-like element in association with the blaCTX-1539 
M-15 gene and the Tn3-like transposon harbouring a blaTEM-1 gene (Canton & Coque, 2006). (e) 1540 
A complex class 1 integron, comprising the class 1 integron and its gene cassettes (dfrA12, 1541 
orfF and aadA12) with 59-be (black ovals), intI1 (integrase gene) and attI (recombination 1542 
site, black circle), the blaCTX-M-14 gene associated with the ISCR1 element and a duplication of 1543 
the qacEΔ1/sul1 tandem (Bae et al., 2007). (f) The blaCTX-M-10 gene located downstream of 1544 
phage-related elements (orf2, orf3, orf4 and DNA invertase) (Oliver et al., 2005; Riaño et al., 1545 
2009). (g) A class 1 integron harbouring the gene cassettes (blaVEB-1 blaOXA-10-like and arr-2-1546 
like gene cassettes) with 59-be (black ovals), intI1 (integrase gene) and attI (recombination 1547 
site, black circle)) (Riaño et al., 2009; Girlich et al., 2001). (h) An In52 class 1 integron 1548 
structure harbouring the blaGES-1, aac(6’)lb’, dfrXVB, clmA4, aadA2 gene cassettes (59-be 1549 
(black ovals), intI1 (integrase gene) and attI (recombination site, black circle)) (Poirel et al., 1550 
2000). (i) A class 3 integron harbouring the gene cassettes (blaGES-1 gene cassette and a fusion 1551 
event between blaOXA-10-type and aac(6’)-lb gene cassettes) with 59-be (black ovals), intI3 1552 
(integrase gene) and attI (recombination site, black circle) (Correia et al., 2003). 1553 
 1554 
 1555 
 1556 
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Fig. 2: Modular schematic structure of the backbones of mobile genetic elements containing 1557 
plasmidic ampC genes. (a) An ISEcp1-like element in association with the blaCMY-2/5 gene. 1558 
The blaCMY-2 gene is the most common ampC β-lactamase gene among Enterobacteriaceae 1559 
worldwide, being related to the ampC genes of Citrobacter freundii (Giles et al., 2004; 1560 
Winokur et al., 2001). The blc and sugE genes showed 96% sequence identity with the two 1561 
genes just found downstream of the Citrobacter freundii chromosomal ampC gene (Giles et 1562 
al., 2004). (b) blaDHA-1, blaCMY-10 and blaCMY-11 in association with ISCR1 in a complex class 1 1563 
integron (59-be: black ovals and attI recombination site: black circle) with aadA2 as gene 1564 
cassette (Lee et al., 2004; Verdet et al., 2000). The blaCMY-10 and blaCMY-11 genes, related to 1565 
chromosomally ampC genes of Aeromonas spp., are evolved from the blaCMY-1 gene. A 1566 
sequence identical to the ISCR1 was found upstream from the blaCMY-10 and blaCMY-11 genes 1567 
(Jacoby, 2009; Lee et al., 2004). The genetic organization of the gene coding for DHA-1 was 1568 
mobilized from the Morganella morganii chromosome and inserted into a sulI-type integron 1569 
(Verdet et al., 2000). (c) schematic representation of the 4252 bp C. freundii-derived 1570 
sequence containing the blaCMY-13 gene (Miriagou et al., 2004). The blaCMY-13-ampR region 1571 
was bound by two directly repeated IS26 elements. 1572 
 1573 
Fig. 3: Schematic representation of the number of studies reporting the presence of the most 1574 
predominant ESBLs among Enterobacteriaceae isolated from healthy (a) and sick animals (b) 1575 
and healthy (c) and sick humans (d) (modified from Tables 4, 5, 6, 7 and 8). 1576 
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Fig. 2 1609 
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